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Regulation of Dopamine Transporter Trafficking by Substrates, Rabs and SNAREs 
 
The plasmalemmal dopamine transporter (DAT) regulates dopaminergic 
neurotransmission by facilitating reuptake of extracellular dopamine (DA).  The 
psychostimulant amphetamine (AMPH) is a substrate of DAT which stimulates DA 
efflux through DAT.  DAT undergoes both constitutive and substrate-regulated 
trafficking and this trafficking further regulates DA action.  To date, most trafficking 
studies focus on DAT endocytosis following prolonged (10 – 60 min) substrate treatment.  
However, little is known about the mechanisms regulating DAT exocytosis or trafficking 
to the plasma membrane.  
The purpose of this thesis was to elucidate the mechanisms by which constitutive 
and rapid stimulated DAT trafficking occur.  Specifically, the role of Rab and SNARE 
(N-ethylmaleimide sensitive factor attachment protein receptor) proteins in constitutive 
DAT trafficking was examined. Additionally, the mechanisms of rapid DAT trafficking 
to the surface in response to substrates were examined.  Our results provide a new model 
whereby (1) Rab 11 and syntaxin 1A (SYN1A)  are required for proper tethering and 
fusion of DAT to the plasma membrane; (2) Rapid substrate treatment induces DAT 
exocytosis in a PKC-β-dependent, D2R-independent manner and; (3) AMPH and SYN1A 
regulate one another’s action on DAT trafficking and function.  
 xi   
 
Taken together DAT trafficking and function are rapidly and specifically 
regulated by intracellular stimuli including protein kinase activation and GTPase protein 
regulation as well as extracellular stimuli including the physiological substrate DA and 
the psychostimulant amphetamine. These data confirm the importance of DAT in 
maintaining proper dopaminergic neurotransmission and demonstrate that homeostatic 
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(nigrostriatal pathway), whereas A10 DA cell bodies originate in the ventral tegmental 
area and project to the nucleus accumbens, also known as the ventral striatum 
(mesolimbic pathway).   Another pathway which originates from A10 DA cell bodies is 
the mesocortical pathway which projects to hippocampus, cerebral cortex, lateral septum 
and the anterior olfactory nucleus.  The mesolimbic pathway is thought to be important 
for setting the ‘emotional tone’ therefore the nucleus accumbens is a key area of study in 
psychiatric disorders including schizophrenia and depression.  The mesocortical pathway 
is important in cognition since the frontal cortex is a major site of these neuron 
projections.  It is thought that the combination of these two pathways, i.e, a 
mesocorticolimbic pathway contributes to psychiatric and cognitive diseases.  Overall, 
the A9 and A10 DA pathways constitute a principal component in what is known as the 
“reward” pathway.  It is accepted that dopaminergic neurotransmission through these 
pathways functions is a signal that a reward, be it natural (food, sex) or unnatural 
(synthetic drugs) (Koob 2009). This “reward” element of the DA pathway makes it 
extremely important in all types of addiction.  In addition, the reinforcing effects and 
habit development leading to drug addiction involves the neurocircuitry of these A9 and 
A10 dopamine pathways (Koob 2009). 
Dopamine is synthesized by conversion of tyrosine to L-DOPA by the rate-
limiting enzyme tyrosine hydroxylase.  L-DOPA is then converted to DA by the enzyme 
aromatic amino acid decarboxylase (AADC).  In noradrenergic terminals, DA can be 
converted to norepinephrine (NE) by the enzyme dopamine-β-hydroxylase.  Although 
this thesis focuses solely on the brain, it is important to note that DA is also a crucial 
neurotransmitter in kidney function.   
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Stimulation of a DA neuron causes a calcium-triggered exocytosis of DA vesicles 
and following vesicle fusion, DA is released into the synaptic cleft.  DA is metabolized 
by monoamine oxidase which is located on the outer mitochondrial membrane.  It can 
also be metabolized extra-neuronally by catechol-O-methyl transferase enzyme.   
Extracellular DA acts on pre- and postsynaptic DA receptors, whose subtypes are labeled 
D1 – D5.  Dopamine receptors are seven transmembrane G-protein coupled receptors.  
The D1-like family of receptors include D1 and D5 receptors which couple to Gs proteins 
that stimulate signal transduction through activation of adenylyl cyclase and subsequent 
cyclic AMP production.  In contrast D2-like receptors including D2, D3 and D4, couple 
to Gi/o proteins and are inhibitory to signal transduction.  Both D1 and D2 receptors are 
located in the whole striatum (Girault & Greengard 2004).  D3 receptors are located in 
limbic areas of the brain and are considered potential therapeutic targets for treatment of 
drug addiction (Heidbreder et al. 2005).  D2 receptors exist in two forms, short and long.  
The short form D2 receptors (D2S) are thought to predominantly be auto-receptors.  D2 
auto-receptors are located on the presynaptic membrane and are involved in the 
regulation of exocytotic DA release.  For example, when DA is released into the synaptic 
cleft following exocytosis, it acts on D2 auto-receptors which inhibit both the synthesis of 
DA and exocytosis of DA-containing vesicles.  
 
Dopamine Transporter (DAT) – structure, function and location 
The amount of extracellular DA in the synapse dictates the strength and 
endurance of dopaminergic neurotransmission, thus it is critical that DA levels be tightly 
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the intracellular side based on the amino acid sequence and hydropathy plot (Figure 1.2). 
Both termini contain consensus sites for various protein kinases.  Consensus sequences 
for protein kinase C (PKC) and protein kinase A (PKA) are located at the N-terminus and 
consensus sequences for PKA and calcium/calmodulin-dependent kinase II (CAMKII) 
sites are located at the C-terminus (Giros & Caron 1993).  Phosphorylation of the N-
terminus of DAT is observed (Foster et al. 2002), and mutating serines on the N-terminus 
of DAT has functional consequences (Khoshbouei et al., 2004).  However, to date, no 
studies have identified the specific sites of phosphorylation on DAT thus it is not known 
whether these consensus sites are phosphorylated or whether there is an indirect 
phosphorylation.  DAT has a large second extracellular loop that is heavily glycosylated.  
Although no crystal structure for monoamine transporters currently exists, a bacterial 
homologue of Na+/Cl- dependent transporters was recently crystallized (Yamashita et al. 
2005).  This crystal structure confirmed the notion that monoamine transporters have a 
conformation that allows for substrate binding from the extracellular space (outward 
facing), a transitional state (substrate occluded) and lastly a conformation that allows for 
substrate binding from the intracellular space (inward facing).  
In 1996, Giros and colleagues used DAT knock-out mice to demonstrate the role 
of DAT in DA clearance (Giros et al. 1996).  Mice lacking the dopamine transporter have 
increased locomotor activity as compared to wild-type mice and high levels of DA in the 
synapse.  These knock-out mice also have reduced DA tissue content, DA release and DA 
receptors relative to WT controls, underscoring the importance of DAT in maintenance of 
DA levels. 
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Experiments done in cellular models with cloned transporters demonstrated that 
cell systems were a reasonable model for the physiological DA system (Giros et al. 
1992).  As a result, the DAT has been studied in a variety of heterologous cell lines 
including, but not limited to, pheocromocytoma PC12, human embryonic kidney (HEK), 
madin-darby canine kidney (MDCK), and neuroblastoma (N2A) cells.  The intracellular 
location of DAT varies in heterologous cell systems.  For example, in PC12 cells, DAT is 
located in endosomes which are less than 50 nm (Loder and Melikian, 2003).  In this cell 
line, DAT was absent from large dense-core vesicles and recycled with transferrin (Loder 
& Melikian 2003).  However, in MDCK cells, DAT is located in lysosomes as well as 
endosomes (Daniels & Amara 1999, Melikian 2004).  Interestingly, these two cell lines 
show differential regulation of DAT trafficking which may be due to the difference in 
intracellular localization. 
 
DAT in neurological and psychiatric disorders 
Psychosis   
Psychosis is broadly defined as an impaired contact with reality. One prominent 
type of psychosis is schizophrenia which affects 1.1% of the U.S. population over age 18 
(National Institutes of Mental Health).  “Positive symptoms” in psychosis include 
auditory hallucinations, delusions, hyperactivity and combativeness and are generally 
treatable.  “Negative symptoms” in psychosis include flat affect and severe withdrawal 
and are much more difficult to treat.  A wealth of pharmacological evidence suggests that 
the phenotype of excessive behavior (positive symptoms) in psychosis occurs as a result 
of greater dopaminergic activity in the basal ganglia and has led to the so-called “DA 
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hypothesis of schizophrenia” (Lieberman et al. 1997).  One study which provided 
important evidence for the DA hypothesis of schizophrenia was by Laruelle et al., (1994) 
who found that AMPH-stimulated DA release through DAT as measured indirectly by 
single photon emission computed tomography (SPECT) imaging was greater in drug-free 
schizophrenic patients than in age matched controls.  These data suggest that there are 
alterations in DAT activity that may contribute to schizophrenia. 
Parkinson’s Disease    
Parkinson’s Disease is a neurological disorder with hallmark symptoms including 
cogwheel rigidity of motion, tremor, shuffling gait and bradykinesia.  The molecular 
hallmark symptoms of the disease include pronounced loss of dopaminergic tone (Girault 
& Greengard 2004).  Dopamine neuron loss may be more or less severe depending on the 
brain region.  The relative loss of DA neurons correlates with the amount of DAT 
expressed in these specific brain regions; the higher the amount of DAT expression, the 
more vulnerable the DA neurons (Bannon 2005).  Furthermore, imaging studies using 
DAT markers show that there is a decrease in DAT labeling in Parkinson’s Disease 
patients as compared to control that correlates with the severity of Parkinson’s Disease 
(Kugaya et al. 2000).  DAT may contribute to the neurotoxicity associated with 
Parkinson’s Disease since it can take up certain neurotoxins such as MPP+ into the cell 
which leads to cell death (Storch et al. 2004).  Taken together, these data suggest that 
DAT may be an important target for treatment of Parkinson’s Disease.  Current 
symptomatic treatments include L-DOPA (precursor to dopamine), as well as DA 
agonists pramipexole and ropinirole.  To date, there is no cure for Parkinson’s Disease; 
therefore much research has focused on understanding the disease. 
 
 8   
 
Attention Deficit Hyperactivity disorder (ADHD) 
ADHD is a disorder characterized by inattentiveness and 
hyperactivity/impulsivity (Mazei-Robinson & Blakely 2006).  The DAT blocker 
methylphenidate (Ritalin®) and DAT substrate and releaser D-amphetamine (Adderall®) 
are commonly used in the treatment of ADHD.  It is somewhat paradoxical that a drug 
that acts as a psychostimulant in normal subjects would be used to treat a disorder 
characterized by hyperactivity.  However, these psychostimulants have been shown to 
ameliorate hyperactive symptoms in humans with ADHD as well as animal models of 
ADHD (Mazei-Robinson & Blakely 2006).  The differential action of these drugs in 
ADHD subjects v. normal subjects points to a difference in the functional characteristics 
of DAT and/or other monoamine transporters between these groups.  Several studies have 
demonstrated a modest but significant increase in DAT labeling in adults with ADHD as 
compared to controls (Mazei-Robinson & Blakely 2006).  Furthermore, studies have 
demonstrated a link between genetic polymorphisms of DAT and ADHD (Hahn & 
Blakely 2007).  Specifically the 3’VNTR (variable number of tandem repeats) DAT 
mutation is a prevalent mutation whose characteristics may shed light on the mechanism 
by which dopaminergic tone is set to ‘normal’ following psychostimulant treatment.  In 
addition, specific DAT protein variants have been identified in ADHD cohorts and these 
are currently being examined. 
Drug addiction 
Although both cocaine and AMPH target various monoamine transporters 
including SERT, NET and DAT, the dopaminergic system in particular is thought to be a 
major component of AMPH and cocaine psychostimulant effects.  Numerous studies 
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have demonstrated the importance of the dopaminergic pathway in the reinforcing effects 
of psychostimulants (for review, see (Howell & Kimmel 2008, Koob 2009)).  One 
prominent finding was in the use of DAT knock-out mice.  Intra-peritoneal 
administration of high doses of cocaine (40 mg/kg) or AMPH (10 mg/kg) to DAT knock-
out mice failed to produce any locomotor activity (Giros et al. 1996).  Further evidence 




According to the National Survey on Drug use and Health, there were an 
estimated 731,000 users of methamphetamine in 2007.  Structural homologs of AMPH 
include methamphetamine (METH) and methlyene-dioxy-methamphetamine (MDMA, 
ecstasy) which are both highly abused illicit substances.  Psychostimulant effects of 
amphetamines include euphoria, hyperactivity, insomnia and loss of appetite.  Imaging 
studies using [11C] WIN 35428 as a DAT marker showed that METH users have 
decreased striatal DAT binding as compared to control groups (McCann et al. 2008).  
Similarly, another study using SPECT imaging showed that long term (4 – 12 years) 
METH users showed decreased DAT binding as compared to controls (Chou et al. 2007).  
Interestingly, following a two week abstinence, DAT binding in METH users was not 
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A 2006 survey from the National survey on Drug use and health showed 43.8 
million people reported use of crack or powder cocaine at some time in their life.  
Although it has been reported that DAT knock-out mice still exhibit conditioned place 
preference to cocaine (Rocha et al. 1998, Sora et al. 1998), these findings are strongly 
contested.  A knock-in mouse of a cocaine-insensitive DAT was generated and tested for 
psychostimulant characteristics of cocaine (Chen et al. 2006).  These knock-in mice did 
not display any conditioned place preference to cocaine or cocaine-induced locomotion 
over a wide range of doses (Chen et al. 2006, Tilley et al. 2009) strongly indicating that 
DAT is the site mediating the primary reinforcement effects of cocaine.  Clinical 
evidence from cocaine abusers that were acutely abstinent showed that DAT binding was 
elevated by 20% as compared to controls (Malison et al. 1998). 
 
DAT substrates and inhibitors 
Dopamine is the major substrate for DAT as described above.  Norepinephrine is 
also a substrate for DAT, just as DA is a substrate for NET.  The psychostimulant AMPH 
is a well-known substrate of DAT which competes for DA uptake.  The name 
amphetamine is a condensation of α-methyl-phenethyl-amine.  AMPH is structurally 
similar to DA except that it lacks the hydroxyl groups on the phenyl ring that DA has and 
is therefore not a catechol.  This has important metabolic consequences since enzymes 
like catechol-O-methyl transferase (COMT) can’t breakdown AMPH.  AMPH also acts 
as a competitive inhibitor of DA breakdown by monoamine oxidase since it binds the 
enzyme but is not itself metabolized by it.  
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Inhibitors of DAT include cocaine and methylphenidate.  Inhibitors of DAT 
prevent reuptake of DA by blocking the site of DA transport.  The exact site of inhibitor 
binding is not yet known and is an area of intense investigation.  Blockade of DA 
transport causes an accumulation of extracellular DA, leading to increased dopaminergic 
neurotransmission and a psychostimulant effect. 
 
AMPH-stimulated DA efflux 
As previously discussed, AMPH elicits reversal of DAT resulting in DA efflux.  
There are several competing models for the mechanism of AMPH-stimulated DA efflux.  
The facilitated exchange diffusion model suggests that when AMPH is taken up by the 
transporter it increases the number of inward facing transporter binding sites, stimulating 
DA to bind to the inward-facing transporter and thus increasing reversal of DA transport.  
Under this model proposed by Stein in 1967 and specifically for catecholamine 
transporters by Bogdanski and Brodie in 1969, only one molecule can be released for 
every molecule that is taken up.  The weak base model suggests that AMPH depletes DA 
vesicle pools by alkalinizing the vesicles, thereby increasing the cytosolic level of DA.  
The increased DA concentration then alters the electrochemical gradient such that it is 
more favorable for DAT to release DA into the synaptic cleft (Sulzer et al. 1992, Sulzer 
& Rayport 1990).  Based on this model, AMPH-stimulated DA efflux is independent of 
any interaction between AMPH and DAT (Sulzer et al. 1995).  Data from Galli and 
colleagues suggest that when AMPH is taken up by DAT, there is an increase in 
intracellular sodium availability which alters the charge gradient thereby reversing the 
transporter (Khoshbouei et al. 2003).  
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AMPH-stimulated DA efflux is regulated by protein kinase C (PKC) activity. 
PKC inhibition blocks AMPH-stimulated DA efflux in heterologous cells and rat striatum 
(Johnson et al. 2005b, Kantor et al. 2001).  Activation of PKC with the phorbol ester 
TPA (12-O-tetradecanoylphorbol-13-acetate) mimics the effect of AMPH on reverse 
transport of DA by eliciting an efflux of DA that is cocaine-sensitive and independent of 
extracellular calcium (Kantor & Gnegy 1998). 
DAT trafficking regulation 
Since surface DAT expression shapes dopaminergic neurotransmission, DAT 
trafficking can efficiently regulate neurotransmission.  Indeed, DAT undergoes both 
constitutive and regulated trafficking and this trafficking is often directly related to its 
function (Kahlig & Galli 2003, Melikian 2004).  A common technique used to assess 
DAT trafficking includes biotinylation in which cell surface proteins are labeled with the 
cell impermeant molecule biotin followed by lysis and comparison of biotinylated 
(surface) DAT to lysate (total) DAT.  Subcellular fractionation followed by western blot 
analysis is also a method used to monitor localization of proteins based on their co-
fractionation with marker proteins.  A more pharmacological method of detecting surface 
expression is binding of [3H]WIN35428, a cocaine analog that specifically inhibits DAT.  
Finally, a method used to visualize and quantify DAT distribution is confocal microscopy 
in which one can visualize the amount of DAT surface protein v. DAT intracellular 
protein.  Confocal microscopy can be performed with live cells provided a fluorescent tag 
such as green fluorescent protein or yellow fluorescent protein is fused to the protein of 
interest.  Each of these methods has pitfalls and strengths.  For example, although 
confocal microscopy allows for visualization of protein distribution, it is difficult to 
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accurately quantify protein levels relative to the amount of fluorescence that is detected.  
Often, researchers use [3H]DA uptake as a measure of DAT surface expression.   
Constitutive DAT trafficking 
Approximately 30 – 40 % of total DAT is located on the plasma membrane of 
DAT-N2A and DAT-PC12 cells (Loder & Melikian 2003, Little et al. 2002).  DAT 
constitutively recycles at a rate of 3-5 % per min in DAT-PC12 cells (Loder & Melikian 
2003).  DAT likely exists in the plasma membrane in some oligomeric state which is 
necessary for proper DAT trafficking and function (Sorkina et al., 2003; Torres et al., 
2003).  Both basal and PKC-induced DAT internalization was found to be clathrin-
dependent in a study which utilized knock-down of clathrin or dynamin II proteins 
(Sorkina et al. 2005).  A specific ten amino acid sequence (FREKLAIYA) in the DAT C-
terminus was found to rescue (promote) internalization of an endocytosis-defective 
reporter protein (Holton et al. 2005).  This sequence was conserved across the SLC6 
family representing an endocytic signal specific to neurotransmitter transporters yet 
distinct from classical endocytic signals.  In contrast, there was no rescue of 
internalization when the N-terminus was fused to the same endocytic-defective reporter 
proteins (Holton et al. 2005). 
An extensive body of work demonstrates regulation of DAT trafficking in 
response to substrates, inhibitors and phosphorylation (For extensive reviews: (Kahlig & 
Galli 2003, Zahniser & Doolen 2001).  
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DA-stimulated DAT trafficking 
Decreased DAT surface expression is observed following prolonged treatment of 
DA in heterologous cell lines (Chi & Reith 2003, Little et al. 2002, Saunders et al. 2000).  
One hour of DA treatment (10 µM) reduced [3H]DA uptake to 73% of control and 
surface DAT redistribution to the cytosol as measured by confocal microscopy in hDAT-
HEK cells (Saunders et al. 2000).  In contrast to the above studies, no DA-induced DAT 
internalization was detected in MDCK cells (Daniels & Amara 1999).  DA-induced 
internalization has also been demonstrated in Xenopus laevis oocytes (Gulley et al. 2002).  
In this study, DA was administered for 40 – 60 min and DAT associated currents were 
reduced along with the decrease in surface expression. 
All of the above studies utilized prolonged DA treatment ranging from ~ 40 – 60 min in a 
variety of systems.  One study looked at rapid treatment of DA (30 µM, 30 sec) in rat 
striatal synaptosomes and no change in DAT surface expression was observed (Johnson 
et al. 2005a). 
AMPH-stimulated DAT trafficking 
Prolonged AMPH treatment 
Fleckenstein et al (1997b) first demonstrated that METH acutely alters DAT 
function (Fleckenstein et al. 1997a).  In this study, METH significantly decreased DAT 
function (measured by [3H]DA uptake) 1 hr after a 5, 10 or 15 mg/kg injection.  Similar 
studies were performed using high doses of AMPH (10 mg/kg) and MDMA (15 mg/kg) 
and these were also found to reduce DAT function (Fleckenstein et al. 1999).  These 
studies did not determine whether changes in DAT surface expression were concomitant 
with decreased DAT function.  Sandoval et al., 2001 demonstrated that METH (10 µM) 
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decreased [3H]DA uptake in striatal synaptosomes following 5 – 30 minutes of treatment 
with no effect on [3H]WIN35428 binding. 
In heterologous cells, studies were done to determine whether changes in [3H]DA 
uptake correlated with DAT surface expression.  FLAG-hDAT HEK cells were treated 
with AMPH (2 µM, 1 hr) and a significant decrease in [3H]DA uptake and DAT surface 
expression was observed (Saunders et al. 2000).  
Rapid AMPH treatment 
We demonstrated rapid AMPH-stimulated DAT trafficking to the surface at times 
corresponding to AMPH -stimulated DA efflux.  A 1-min treatment of rat striatal 
synaptosomes with 3 µM AMPH induced a significant increase (~150% of control) in 
DAT cell surface expression (Johnson et al. 2005a) which was abolished in the presence 
of cocaine.  The AMPH-stimulated increase was short-lived lasting for the first 2.5 
minutes and returning to baseline by 10 minutes of treatment.  After 30 min of treatment 
DAT surface expression was reduced to approximately 50% of control which 
corresponds to data from other researchers (Kahlig et al. 2004).  When synaptosomes 
were pretreated with AMPH followed by washout and measured for [3H]DA uptake, no 
change in uptake was seen as compared to vehicle (Johnson et al. 2005a).  However, this 
rapid AMPH -stimulated increase in DAT cell surface expression functionally enhanced 
AMPH-stimulated DA efflux. These results suggest that the DAT that is brought to the 
surface following short AMPH stimulation is primarily functioning to release DA as 
opposed to taking up DA.  In order to determine whether DAT surface expression 
increased due to increased trafficking towards the surface as opposed to decreased 
trafficking away from the surface, we performed reversible biotinylation studies.  In these 
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experiments, surface DAT molecules were first labeled with biotin and then allowed to 
internalize.  Following internalization, labeled DAT that remained on the surface was 
stripped.  Treatment with AMPH was then performed for one minute.  If AMPH brings 
DAT molecules from the cytosol to the surface, there should be an increase in the number 
of labeled DAT molecules on the surface and a corresponding decrease in labeled DAT 
molecules in the cytosol as compared to vehicle treated cells.  Indeed, the results indicate 
less cytosolic labeled DAT following AMPH treatment versus vehicle treatment 
indicating that AMPH facilitates exocytosis of DAT as opposed to inhibiting endocytosis 
of DAT (Johnson et al. 2005a).  
Cocaine-induced DAT trafficking 
Several studies have been performed to determine whether chronic cocaine use 
results in alterations of dopaminergic neurotransmission, particularly in DAT activity (for 
extensive review see (Kahlig & Galli 2003).  Studies using post-mortem brain tissue from 
chronic cocaine users show increased [3H]WIN 35428 binding in the caudate putamen 
and nucleus accumbens compared to age-matched controls (Little et al. 1993).  Similar 
results were found in a report by Mash et al. (2002) which showed both an increase in 
[3H]WIN 34428 binding and in Vmax of [3H]DA uptake (Mash et al. 2002). 
Studies in heterologous cell lines demonstrate acute regulation of DAT upon cocaine 
exposure.  DAT-HEK cells treated with 10 µM cocaine for 10 min increased [3H]DA 
uptake by 30% compared to control (Daws et al. 2002).  Another report found an increase 
in surface DAT as measured by [3H]WIN35428 binding upon 1 µM cocaine treatment 
after 12 and 24 hours, however, no rapid induction was found (Little et al. 2002).  
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Protein kinase C-induced DAT trafficking 
There are several consensus sequence sites for PKC and PKA phosphorylation on 
the N- and C-termini of DAT.  Therefore, much work has gone into trying to uncover the 
role of PKC activity in DAT function.  It is now well established that PKC activity plays 
a role in DAT function, particularly DAT-mediated AMPH-stimulated DA efflux and 
DAT trafficking, however the precise mechanism is still unknown.  PKC activation by 
phorbol esters such as phorbol myristate acetate (PMA) downregulates DAT activity 
and/or DAT surface expression in heterologous cells: MDCK, PC12, Sf9, Cos7 and PAE 
as well as primary Xenopus laevis oocytes (Daniels & Amara 1999, Loder & Melikian 
2003, Melikian & Buckley 1999, Pristupa et al. 1998, Sorkina et al. 2005, Zhu et al. 
1997) for review see (Melikian 2004, Zahniser & Doolen 2001).  These effects of PKC 
are generally observed from 10 – 60 min of treatment.  For example, in DAT-PC12 cells, 
PMA activation of PKC for 30 min resulted in DAT internalization into transferrin 
receptor positive endosomes (Melikian & Buckley 1999).  The extent to which PKC 
downregulates DAT seems to depend on the amount of DAT expressed in the cell (Loder 
& Melikian 2003). 
Insulin-stimulated DAT trafficking 
Based on behavioral studies from diabetic mice, anatomical similarities between 
DAT and insulin receptors, and biochemical data from other monoamine transporters, 
insulin regulation of DAT has been hypothesized (Carvelli et al. 2002).  Carvelli et al., 
(2002) demonstrated that insulin rapidly (2-5 min) increases [3H]DA uptake and DAT 
surface expression in a phosphatidyl inositol 3 kinase (PI3K)-dependent manner.  
Blockade of PI3K with LY294002 in the absence of stimuli (i.e., insulin) caused a 
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reduction in basal DA uptake and DAT surface expression (Carvelli et al. 2002).  This 
group also demonstrated that AMPH-induced DAT internalization could be reversed by 
insulin treatment in an Akt-dependent manner (Garcia et al. 2005).  Inhibition of Akt, 
similar to inhibition of PI3K, resulted in decreased DAT surface expression and [3H]DA 
uptake.  Taken together, these data demonstrate a mechanism by which insulin activates 
PI3K which phosphorylates Akt and allows for normal recycling of DAT to the plasma 
membrane.  In addition, the ability for the insulin signaling cascade to affect AMPH-
induced DAT internalization, suggests a complimentary or converging pathway. 
D2-mediated DAT trafficking  
In addition to regulating the amount of exocytotic DA that is released, D2 
receptors modulate the surface expression and function of DAT (Mayfield & Zahniser 
2001, Meiergerd et al. 1993).  Dopamine treatment of Xenopus laevis oocytes 
significantly upregulated [3H]DA uptake and DAT surface expression as measured by 
[3H]WIN35428 binding.  These data correspond with recent studies by Bolan et al., 
(2007) which demonstrate that D2 regulates DAT surface expression in an agonist-
dependent manner.  In these studies, the D2 agonist quinpirole rapidly increased DAT 
surface expression.  In contrast, Lee et al., (2007) identified a protein-protein interaction 
between D2 and DAT which occurred independently of agonist treatment.  This 
interaction appeared to be functional since co-expression of D2 and DAT resulted in 
increased surface expression of DAT indicating that the direct interaction allowed for co-
trafficking of the two proteins to the plasma membrane.  Taken together, there may be 
multiple mechanisms including physical interaction and/or signaling pathway activation 
by which D2 receptors regulate DAT function.   
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Modulators and Regulators of transporter trafficking 
The mechanisms of transporter trafficking are still poorly understood.  Insights 
from receptor trafficking may provide information about yet unidentified transporter 
trafficking properties.  There is now evidence that transporter trafficking has similar 
mechanistic properties to that of receptor trafficking.  DAT undergoes constitutive 
internalization into early and recycling endosomes as indicated by its co-localization with 
endosomal markers (Melikian & Buckley 1999, Sorkina et al. 2003, Sorkina et al. 2005).  
Little is known about regulation of DAT trafficking and specifically how DAT undergoes 
trafficking to the plasma membrane.  Two prominent protein families discussed in this 
section may be key regulators of DAT trafficking to the plasma membrane.  Rab and 
SNARE proteins may work in conjunction to facilitate the translocation, tethering and 
fusion events necessary to increase DAT surface expression.  
Rab proteins 
Function of Rabs 
Rab proteins are a large family within the Ras superfamily.  Rabs are GTPase 
proteins that cycle between a GTP-bound state in which they are able to bind effector 
proteins and a GDP-bound state in which they are inactive.  Rabs facilitate protein 
trafficking from one compartment to another. As shown in Figure 1.3, there are numerous 
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GLUT4).  Both GLUT4 and DAT are localized to the endocytic recycling compartment 
and both co-localize with Rab 11.  
Rab and DAT 
The DAT recycles into the endocytic recycling compartment in DAT-PC12 cells 
(Melikian & Buckley 1999).  Loder and Melikian (2003) demonstrated that DAT proteins 
recycle into Rab 5 containing endosomes in PC12 cells.  Treatment with the PKC 
activator PMA or the DAT substrate AMPH for 1-2 hours induced DAT internalization 
into Rab 11- and Rab 5-containing compartments (Sorkina et al. 2003).  Notably, the 
authors in that study found a small amount of DAT co-localized in Rab 11-containing 
endosomes in the absence of treatment indicating constitutive trafficking to these 
endosomes.  Furthermore Rab proteins have been implicated in trafficking of other 
transporters such as the GLUT4 (Zaid et al. 2008).  The role of Rab protein function in 
DAT trafficking and activity has not been investigated. 
SNARE proteins 
In order for protein recycling between intracellular and membranous 
compartments to occur, fusion events must take place.  Of particular relevance to this 
thesis is how membrane bound proteins such as DAT are trafficked from intracellular 
endocytic compartments to the plasma membrane.  The fusion process typically involves 
tethering, docking (discussed in the previous section) and then fusion.  Soluble NSF-
sensitive attachment protein receptor (SNARE) proteins are essential in classical fusion 
events.  A SNARE complex consists of two plasma membrane bound proteins syntaxin 
and SNAP25 and the vesicle bound protein VAMP (vesicular associated membrane 
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Thesis goals and hypotheses 
As described above, there are several mechanisms by which DAT trafficking may 
be regulated.  It is still not completely understood how various mechanisms may 
converge into complimentary or opposing pathways.  Many of the trafficking studies 
described above with the exception of the Gnegy laboratory’s work (Johnson et al. 
2005a) demonstrate prolonged (min – hr) treatments of substrates to induce DAT 
internalization. While DAT internalization is an important component of dopaminergic 
neurotransmission, an equally important component is DAT trafficking that occurs 
simultaneous to physiological responses.  Therefore, Aim I of this thesis is to characterize 
the kinetics and mechanism of rapid AMPH-stimulated DAT trafficking using real-time 
measurements and determine whether this effect is substrate specific.  The hypothesis for 
Aim I is that rapid DAT trafficking to the surface is not specific to AMPH, but may be 
extended to the natural substrate DA as well.  Furthermore, based on evidence from 
Johnson et al., 2005 which shows a role of PKC-β in AMPH-stimulated DA efflux, I 
hypothesize that PKC-β contributes to the translocation of DAT to the surface upon 
substrate treatment.  
 In order to understand the mechanism of action of psychostimulants acting on 
DAT, much work has gone into elucidating the mechanism of stimulated DAT 
trafficking.  However, it is important to also delineate the mechanism by which DAT 
recycles in a basal or constitutive state. Indeed, based on data from Loder and Melikian, 
2003, we now know that DAT constitutively recycles with a t1/2 of 13 min in 
heterologous DAT PC12 cells.  The endocytic pathway through which DAT recycles is 
still poorly understood.  Furthermore, it is likely that there are trafficking proteins that 
facilitate the recycling of DAT as well as the tethering of DAT to the plasma membrane. 
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In Aim II, Rab proteins are investigated as potential regulators of constitutive DAT 
recycling.  Based on the role of Rab 11 in endocytic recycling towards the plasma 
membrane (Zerial & McBride 2001), and the current literature on DAT recycling, I 
hypothesized that Rab 11, and possibly Rab 8 may play a role in DAT trafficking to the 
surface.       
  Various proteins may be involved in the trafficking of DAT to and from the 
plasma membrane.  Particularly for DAT fusion to the plasma membrane, SNARE 
proteins are likely candidates as they are involved in fusion of transporters within the 
same class as DAT including NET and GAT1 (Quick 2006).  The SNARE protein 
syntaxin is known to directly interact with the N-terminus of DAT and regulate AMPH-
stimulated DA efflux through DAT (Binda et al. 2008, Lee et al. 2004).  However, it is 
not known how syntaxin regulates constitutive DAT trafficking and function.  Aim III 
will determine the role of syntaxin in basal DAT trafficking and function.  In addition, 
the specific conformation of syntaxin when bound to DAT will be determined in order to 
elucidate the characteristics of the syntaxin/DAT interaction.  I hypothesize that DAT 
trafficking towards the plasma membrane requires binding to syntaxin in its open 
conformation which would allow for syntaxin binding to other SNARE proteins and 
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Chapter II  
 
 
Dopamine and Amphetamine Rapidly Increase Dopamine Transporter Trafficking 




Rapid treatment (1 min) of rat striatal synaptosomes with low dose amphetamine 
(AMPH) increases surface expression of the dopamine transporter (DAT).  Using mouse 
neuroblastoma N2A cells stably transfected with GFP-DAT we demonstrate the real-time 
substrate-induced rapid trafficking of DAT to the plasma membrane using total internal 
reflection fluorescence microscopy (TIRFM).  Both the physiological substrate, 
dopamine (DA), and AMPH began to increase surface DAT within 10 sec of drug 
addition and steadily increased surface DAT until removal 2 min later.  The substrate-
induced rise in surface DAT was dose-dependent, was blocked by cocaine and abated 
after drug removal.  While individual vesicle fusion was not visually detectable, 
exocytosis of DAT was blocked using both tetanus neurotoxin and botulinum neurotoxin 
C to cleave SNARE proteins.  Notably, the DA-induced increase in surface DAT was 
cocaine-sensitive but D2-receptor independent.  TIRFM data were confirmed in human 
DAT-N2A cells using biotinylation and similar effects were detected in rat striatal 
synaptosomes.  A specific inhibitor of protein kinase C-β blocked the substrate-mediated 
increase in surface DAT in both DAT-N2A cells and rat striatal synaptosomes.  These 
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data demonstrate that the physiological substrate, DA, and AMPH rapidly increase the 
trafficking of DAT to the surface by a mechanism dependent upon SNARE proteins and 
protein kinase C-β but independent of dopamine D2 receptor activation.  Importantly, this 
study suggests that the reuptake system is poised to rapidly increase its function upon DA 
secretion in order to tightly regulate dopaminergic neurotransmission. 
Introduction 
Dopaminergic neurotransmission is crucial for normal physiological functions as 
well as neurological and psychiatric diseases including drug addiction (Giros & Caron 
1993) and is regulated by the level of synaptic DA.  Extracellular DA is removed from 
the synapse by uptake into the nerve terminal through the Na+/Cl- dependent dopamine 
transporter (DAT).  The psychostimulant AMPH is a DAT substrate which, when taken 
up into the nerve terminal, causes reversal of DAT resulting in DA efflux while cocaine 
blocks reuptake of dopamine. 
Approximately 30 – 40 % of total DAT is located on the plasma membrane of 
heterologous cells (Loder & Melikian 2003, Little et al. 2002).  Since surface DAT 
expression shapes dopaminergic neurotransmission, DAT trafficking can efficiently 
regulate neurotransmission.  DAT undergoes both constitutive and substrate-mediated 
trafficking which alter its function (Kahlig & Galli 2003, Melikian 2004).  Substrate-
induced DAT trafficking has, until recently, focused on demonstrations of DAT 
internalization following prolonged, higher-dose substrate treatment.  Both DA, the 
physiological substrate, and AMPH induce DAT internalization in heterologous cells, 
Xenopus laevis oocytes and striatal synaptosomes after 40 – 60 min of exposure (Chi & 
Reith 2003, Gulley et al. 2002, Saunders et al. 2000).  Similarly, a high-dose AMPH 
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injection reduced DAT function in rat striatum (Fleckenstein et al. 1999).  Of interest, 
however, is how substrates alter DAT trafficking at times commensurate with their initial 
action at the transporter. To that end, our lab demonstrated rapid AMPH-induced DAT 
trafficking to the surface at times corresponding to AMPH-stimulated DA efflux.  A 1-
min treatment of rat striatal synaptosomes with 3 µM AMPH induced a significant 
increase in DAT cell surface expression (Johnson et al. 2005a).  By 30 min of treatment 
DAT surface expression was reduced.  Importantly, this rapid AMPH-induced increase in 
DAT cell surface expression functionally enhanced AMPH-induced DA efflux.  
Although biotinylation and confocal microscopy are commonly used to monitor 
trafficking, they are limiting in temporal and spatial resolution, respectively.  
Investigation of plasma membrane processes is aided by live cell imaging using total 
internal reflection fluorescence microscopy (TIRFM), which provides real time resolution 
coupled with the ability to sensitively detect and analyze cytosol to plasmalemmal 
membrane movement of vesicles and granules.  Total Internal Reflection Fluorescence 
Microscopy (TIRFM, depicted in Figure 2.1) is a unique tool that allows one to focus 
primarily on events occurring close to the membrane.  
In the present study we investigated, utilizing the high temporal and spatial 
resolution available in TIRFM, the dynamics of DAT trafficking to the plasma 
membrane.  We found that within seconds of addition of AMPH or, notably, the 
physiological substrate DA, there were changes in surface expression of DAT with 
maximal increases within one minute.  The rapid increase in DAT was blocked by 
transfection of the light chains of botulinum neurotoxin C (BoNT C) and tetanus 
neurotoxin (TeNT) which cleave t- and v-SNARE proteins, respectively, and prevent 
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vesicle fusion.  The substrate-induced increase in DAT surface expression was modulated 
by a protein kinase C-mediated pathway and was independent of D2 receptor function.  
These data suggest a substrate-mediated trafficking mechanism which directly and 
rapidly regulates DAT surface expression to increase DA clearance.  
Materials and Methods 
Materials. 
 D-amphetamine sulfate, dopamine, GBR12935, quinpirole and sulpiride were 
purchased from Sigma. LY379196 was a generous gift from Eli Lilly and Company. 
Generation of GFP-DAT cDNA.  
Rat dopamine transporter with a fluorescent tag (GFP-DAT) was created by 
fusing the coding region of enhanced green fluorescent protein (EGFP) from pEGFP-C2 
vector (Clontech) to the N terminus of the rat DAT cDNA between EcoRI and KpnI sites 
in the multi-cloning site of the vector. 
Cell culture and stable cell lines.  
GFP-DAT cDNA was transiently transfected into the N2A cell line using the 
Lipofectamine Plus reagent kit (Invitrogen, Carlsbad, CA).  A stable cell line was 
generated through selection with Geneticin (Invitrogen, Carlsbad, CA) over several 
weeks.  Stable human DAT N2A cells were a generous gift of Dr. Karley Little 
(University of Michigan, VA hospital). N2A cell lines were grown in Opti-MEM I 
supplemented with 10 % Bovine Growth Serum, 1 % penicillin/streptomycin and 400 
µg/ml geneticin for stable maintenance.  D2R short form DNA was kindly provided by 
Dr. Roger Sunahara (University of Michigan, Ann Arbor) and was transiently transfected 
into GFP-DAT N2A cells using the Lipofectamine Plus reagent kit.  In control cells, 
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empty vector DNA was transiently transfected. Forty-eight hours after transfection, 
TIRFM experiments were performed. In experiments using neurotoxins, N2A cells were 
transiently co-transfected with GFP-DAT and the light chain form of TeNT or the light 
chain form of BoNT C.  Control cells were co-transfected with GFP-DAT and empty 
vector. 
TIRFM Image acquisition & Perfusion Experiments. 
 GFP-DAT N2A cells were plated onto No. 1.5 glass coverslips coated with 0.5 
mg/ml poly-D-lysine (Sigma).  Coverslips were placed into a closed chamber (Harvard 
apparatus) and KRH buffer composed of (in mM): 25 HEPES, 125 NaCl, 4.8 KCl, 1.2 
KH2PO4, 1.3 CaCl2, 1.2 MgSO4, and 5.6 glucose was added to cover the glass.  Micro-
perfusion of individual cells was performed at ~27°C using a six-chamber perfusion 
apparatus equipped with a quartz pipette (inner diameter: 0.2 µm) that was positioned 
near the cell being imaged.  Cells were continuously perfused throughout image 
collection with KRH buffer or various drugs dissolved in KRH using a computer-
controlled perfusion apparatus (model DAD-6VM; ALA Scientific Instruments, 
Westbury, NY).  Total Internal Reflection Fluorescence was achieved using methods 
described previously with minor changes (Allersma et al. 2006). Prismless (through-the-
objective)  TIRFM was obtained using an Argon ion laser (488 line; Melles Griot 
[Carlsbad, CA] model 35-LAP-431-208  directed through a custom side port to a side-
facing dichroic mirror Q495LPw/AR (Chroma Technology) and a HQ500 LP emission 
filter (Chroma Technology, Brattleboro, VT) on an Olympus IX70 (inverted) microscope 
(Olympus, Melville, NY).  The beam was focused on the periphery of the back focal 
plane of an oil immersion objective (60X 1.49 numerical aperture, Olympus).  The laser 
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beam was incident on the coverslip at an angle that resulted in an evanescent field with a 
decay constant of ~ 100 nm.  Digital images were captured using a high sensitivity CCD 
camera (Andor iXon+, EM-CCD, BV, 512x 512 pixels).  Images were acquired at 0.5 Hz 
with exposure times of 50 – 100 ms.  In general, cells were perfused with three solution 
changes: 120 sec of KRH or test drug, 120 sec of DAT agonist with or without test drug, 
and 60 sec of KRH (150 frames total).  For details, see individual experiments.  For all 
TIRFM experiments, the first 100 sec of baseline perfusion are omitted in the graphs.  
TIRFM Image Quantification. 
 Using the Image J program (NIH software), each cell was traced and analyzed for 
the mean fluorescence intensity over 150 frames.  Background values were obtained by 
measuring a blank region from each frame and taking the average background of the 
frames. Data are plotted as mean arbitrary fluorescent units (AFU) = mean cell intensity 
minus average background intensity.  Cells are normalized to 100 AFU at t = -30 sec 
before DAT agonist addition.  Statistical significance was determined by 2-way analysis 
of variance using Prism 5 or by comparison of individual time points with buffer controls 
using 2-tailed Student’s t test.   
Biotinylation of human DAT-N2A cells. 
 Cells were washed with KRH and treated with the substrates AMPH or DA for 1 
min at 37°C. In some cases a pretreatment of 200 nM LY379196 was given prior to 
substrate treatment (see figure legends for detail).  The reaction was quenched using 
excess 4°C PBS/Ca/Mg.  All remaining steps were performed at 4°C to prevent further 
trafficking.  Cells were washed with PBS/Ca/Mg and surface expression of DAT was 
determined by reacting the surface proteins with 1.5 mg/ml sulfo-NHS-SS-biotin (Pierce, 
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Rockford, IL) at 4°C with constant rotation.  Excess biotin was quenched by incubating 
cells with 100 mM glycine, followed by two washes of 100 mM glycine in PBS/Ca/Mg 
buffer.  Cells were lysed in solubilization buffer (in mM: 25 Tris, 150 NaCl, 1 
ethylenediaminetetraacetic acid (EDTA), 5 N-ethylmalemeide, phenylmethylsulfonyl 
fluoride and 1% triton-X 100) containing a fresh protease inhibitor cocktail tablet 
(Roche) and centrifuged at high speed to obtain soluble protein.  Cells were analyzed for 
protein content and ~100-200 µg protein was reacted with streptavidin beads (Pierce, 
Rockford, IL) to isolate surface protein.  Streptavidin beads were washed 3X with 
solubilization buffer and protein was eluted in sample buffer composed of 250 mM Tris 
pH 6.8, 25 mM EDTA, 10 % sodium dodecyl sulfate, 25 % sucrose, 0.5 % bromophenol 
blue supplemented with 100 mM dithiothreitol.  A portion of protein (~10-20 µg) was 
saved for total DAT measurement (lysate).  Surface and total DAT samples were resolved 
using SDS-PAGE (10-12% Tris-glycine gel).  Western blot analysis was performed using 
a monoclonal anti-DAT antibody (MAB369, Chemicon).  Protein was detected using 
West Pico (Pierce, biotin) or Amersham (lysate) electrochemiluminescence detection.  
Western blot bands were quantified using Scion Image software.  Data are expressed as 
the optical density (OD) units of the biotinylated fraction/OD of the lysate.  
Quinpirole-induced DA uptake 
 Human DAT-N2A cells were treated with either KRH or 10 µM quinpirole for 
15 min at 37°C. [3H]DA (30 nM, 34.4 µCi/µl, Perkin Elmer) + unlabeled DA were added 
to cells to initiate DA uptake in the presence or absence of the DAT blocker 10 µM 
GBR12935 to determine non-specific binding.  After 5 min of incubation, cells were 
filtered onto GFC Whatman filters and washed three times with excess cold PBS.  Filters 
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were dried and counted on a Beckman scintillation counter. 
Biotinylation of rat striatal synaptosomes 
 Synaptosomes were prepared as previously described (Johnson et al. 2005a).  
Biotinylation of rat striatal synaptosomes was performed similarly in human DAT N2A 
cells but were conducted in KRB (in mM): 145 NaCl, 2.7 KCl, 1.2 KH2PO4, 1.2 CaCl2, 1 
MgCl2, 10 glucose, 0.255 ascorbic acid, 24.9 NaHCO3.  Synaptosomes were pretreated 
with KRB, 3 µM AMPH, or 10 μM DA at 37°C (AMPH) or room temperature (DA) for 1 
min.  To test the role of PKC-β, synaptosomes were incubated with 100 nM LY379196 
added with the AMPH.  Reactions were stopped by adding 4°C PBS/Ca/Mg buffer and 
washed once with PBS/Ca/Mg to remove residual drugs.  Synaptosomes were lysed in 
RIPAE buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1 % SDS, 1 % 
Triton X-100, 1 % sodium deoxycholate and protease inhibitors).  Surface DAT 
expression was determined as described above for human DAT-N2A cells.  Immunoblot 
analysis was performed using MAB16, monoclonal anti-DAT antibody generously 
supplied by Dr. Roxanne Vaughan, Department of Biochemistry, University of North 
Dakota.  
AMPH-stimulated DA efflux following AMPH pretreatmen. 
 Synaptosomes were pretreated with KRB, 3 µM AMPH, 100 nM LY379196 or 
100 nM LY379196 + 3 µM AMPH for 1 min at 37°C and then washed three times to 
remove all residual AMPH.  AMPH-stimulated DA efflux was performed in resuspended 
synaptosomes as previously described (Johnson et al. 2005a). Briefly, the resuspended 
synaptosomes were separated into 2 portions and incubated with either KRB or 3 µM 
AMPH for 5 min at 37°C.  The reactions were stopped by filtering the samples through a 
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0.2 mm syringe into an internal standard solution (ISS) containing 0.05 M HClO4, 4.55 
mM dihydroxybenzylamine, 1 M metabisulfate and 0.1 M EDTA.  Dopamine was 
measured in the eluate by HPLC-EC analysis.  Total DA was measured by lysing a 
portion of synaptosomes in ISS.  Dopamine efflux was calculated as the percentage of 
total DA in the synaptosomes (DA in eluate/total DA in synaptosomes) following the 
pretreatment.  
Statistical analysis was performed using Graph Pad Prism 5 (Graph Pad, San Diego, CA). 
 
Results 
AMPH increases surface DAT levels in DAT-N2A cells  
Earlier biochemical studies demonstrated an increase in DAT surface expression 
within one minute of AMPH treatment in rat striatal synaptosomes using biotinylation 
(Johnson et al. 2005a).  In this study, real-time DAT trafficking was visually monitored 
in live N2A neuroblastoma cells stably expressing GFP-DAT.  We employed TIRFM to 
analyze the spatial and temporal resolution of rapid DAT trafficking.  TIRFM revealed 
that AMPH had similar effects in GFP-DAT N2A cells as in synaptosomes.  Individual 
cells were perfused with KRH for 120 sec (baseline) followed by 120 sec in the absence 
or presence of AMPH and lastly with KRH for 60 sec (washout).  Figure 2.2 (upper 
panel) shows a representative cell under KRH perfusion 20 sec before AMPH addition (-
20 sec), and 0, 60 and 120 sec after AMPH perfusion.  Hot spots reflect high amounts of 
GFP-DAT and/or regions of the plasma membrane especially close to the glass interface.  
Fluorescence was stable for at least 90 sec before perfusion with AMPH.  Upon perfusion 
with 5 μM AMPH, GFP-DAT intensity increased, shown at 60 sec and 120 sec post drug 
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application in Figure 2.2.  Amphetamine addition increased GFP-DAT intensity in a 
dose-dependent manner.  The curves were statistically different when analyzed by 2-way 
analysis of variance (see legend to Fig. 2.2).  In post-hoc Bonferroni testing, perfusion 
with 1 µM AMPH significantly increased GFP-DAT intensity by 60 sec of treatment 
whereas a significant increase was attained after 42 sec of perfusion with 5 µM AMPH.  
GFP-DAT intensity remained significantly elevated with 5 µM AMPH for another 60 sec 
following washout by KRH whereas 1 µM AMPH treatment was not significantly 
different between KRH and 1 µM AMPH just 18 sec after washout.   
To confirm that the increase in fluorescence in TIRFM reflected increased DAT 
insertion into the plasma membrane, we measured surface expression by biotinylation.  
Biotinylation of DAT-N2A cells, as previously shown in rat synaptosomes, demonstrated 
an AMPH-induced increase in DAT trafficking to the plasma membrane.  Incubation 
with 3 µM AMPH for 60 sec at 37°C resulted in surface DAT that was 150 % of control 
(KRH treatment,  p< 0.01 by paired 2-tailed t-test, n = 4).  These data temporally 
correlate with the TIRFM studies which demonstrate an increase in GFP-DAT intensity 
within 40 – 60 sec of AMPH perfusion.  
In order to determine whether substrate transport was required for substrate-
induced DAT trafficking, biotinylation experiments using a buffer absent of sodium were 
performed.  When NMDG-Cl was substituted for NaCl during the one minute treatment 
of AMPH or DA, no increase in DAT surface expression was detected (data not shown).  
The physiological substrate DA increases surface DAT levels in DAT-N2A cells  
The ability of the substrate, AMPH, to rapidly increase DAT trafficking to the 
plasma membrane raised the possibility that the normally occurring substrate, DA, could 
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have the same effect.  Indeed, DA (10 μM) increased surface DAT with similar kinetics 
and efficacy as AMPH.  Figure 2.3 (upper panel) shows a representative cell under KRH 
perfusion 20 sec before DA addition (-20 sec), and 0, 60 and 120 sec after DA perfusion.  
Perfusion with 10 μM DA increased GFP-DAT intensity, shown at 60 sec and 120 sec 
post DA (Figure. 2.3, upper panel).  In post-hoc analysis of 2-way ANOVA, (see legend 
to Fig. 2.3), DA significantly increased GFP-DAT intensity within 80 sec of treatment 
although a noticeable increase can be seen ~ 40 sec after drug perfusion.  Following 
washout of DA after 120 sec of treatment, the intensity decreases to control (KRH) levels 
within 34 sec of KRH addition.  Comparison of the washout effects of DA with those of 
AMPH suggests that AMPH has the longer-lasting effect on DAT surface expression. 
Since DA-induced DAT trafficking had not been previously demonstrated, we 
confirmed that DAT was physically being inserted into the plasma membrane using 
biotinylation.  Biotinylation studies showed that 10 µM DA treatment resulted in surface 
DAT that was 250% of control (p < 0.05 by paired 2-tailed t-test, n = 5).  
Amphetamine and dopamine increase GFP-DAT intensity through a DAT-dependent 
mechanism 
In order to establish whether an interaction with DAT was required for the 
substrate-induced increase in GFP-DAT intensity, cells were pretreated with 30 µM 
cocaine for 2 min before addition of AMPH or DA.  For simplicity, data are presented at 
three time points: immediately before the addition of substrate (0 time), and 60 sec and 
120 sec after addition of substrate.  At the 0 time, cells have been incubated for 2 min 
with either KRH or 30 μM cocaine.  As shown in Figure 2.4A and 2.4B, cocaine itself 
had no effect on surface DAT intensity.  However, cocaine effectively blocked the 
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increases in surface DAT fluorescence elicited by 5 μM AMPH (Figure 2.4A) or 10 μM 
DA (Figure 2.4B) at 60 and 120 sec.   
SNARE proteins regulate GFP-DAT trafficking to the plasma membrane 
While monoamine transporter recycling to and from the membrane has been 
demonstrated, few studies have focused on the exocytosis of monoamine transporters.  To 
determine whether DAT was undergoing exocytosis upon substrate treatment, we utilized 
the specific neurotoxins, BoNT C and TeNT, which are known to proteolyze the soluble 
N-ethylmaleimide sensitive factor attachment proteins (SNARE) syntaxin 1A and 
vesicle-associated membrane protein (VAMP)/synaptobrevin, respectively.  Cells were 
transiently co-transfected with GFP-DAT and the light chain of either BoNT C or TeNT.  
All cells were perfused with KRH for 2 min followed by 10 μM DA for 2 min.  As shown 
in Fig. 2.5, in cells transfected with BoNT C (gray bars) or TeNT (black bars), DA-
induced DAT trafficking to the plasma membrane was significantly abrogated as 
compared to cells transfected with vector alone.  At no time did DA significantly increase 
the DAT intensity over the 0 time point in neurotoxin-treated cells.  These data indicate 
that the substrate-induced increase in GFP-DAT intensity is an exocytotic event which is 
regulated by SNARE proteins.  
Dopamine increases surface DAT through a D2R independent mechanism 
The experiments involving DA suggest that physiological levels of synaptic DA 
could interact with the DAT to rapidly regulate synaptic levels of DA.  Rapid increases in 
surface DAT in response to DA D2 receptor (D2R) activation, however, have been 
demonstrated in human embryonic kidney cells co-expressing D2R-short and human 
DAT (Bolan et al. 2007).  It is unlikely that the rapid increase in surface DAT in our 
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experiments is mediated by D2Rs because the DA-stimulated increase was blocked by 30 
μM cocaine.  Nonetheless, we felt it important to examine whether any endogenous D2Rs 
in the GFP-DAT-N2A cells could be mediating the effect of DA.  We could not 
unambiguously prove the presence or absence of D2Rs in the N2A cells using 
immunoblotting.  A western blot of N2A cell lysate with a D2 receptor antibody revealed 
a very faint band following overexposure (data not shown) suggesting there could be a 
small number of D2Rs in these cells.  If there are D2Rs present, they appear not to be 
functionally coupled to DA transport.  There was no increase in [3H]DA uptake in 
response to the D2R agonist quinpirole (Figure 2.6A).  In addition, we pretreated GFP-
DAT-N2A cells with 10 µM sulpiride, a D2R antagonist, for 2 min followed by 2 min of 
10 µM DA and examined fluorescent intensity using TIRFM.  Sulpiride alone did not 
affect GFP-DAT intensity and did not block the DA-induced increase when given 
simultaneously with DA (Figure 2.6B).  Since previous experiments in DAT-N2A cells 
overexpressing D2Rs demonstrated a D2R-dependent increase in DAT activity (Bolan et 
al., 2007), we performed TIRFM experiments with cells overexpressing short form D2Rs, 
D2R-S.  We confirmed surface presentation of D2Rs by performing binding assays with 
the D2R antagonist [3H]-spiperone (data not shown).  TIRFM analysis demonstrated that 
there was no difference in the DA-induced increase in DAT surface expression between 
GFP-DAT cells transiently transfected with D2-receptors vs control cells transiently 
transfected with empty vector (Table 2.1).  These data, combined with the lack of 
quinpirole-induced increase in [3H]DA uptake and the blockade of the DA effect by 
cocaine, demonstrate that the DA-stimulated rapid DAT trafficking is D2-receptor 
independent in the N2A cells within our experimental time frame. 
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Because the concept of a DA-induced, DAT-mediated increase in surface DAT is 
novel, we examined whether this could be demonstrated in a more physiologically 
relevant system, rat striatal synaptosomes.  In a previous study, Johnson et al. (2005a) 
found no increase in surface DAT following treatment of rat synaptosomes with 30 µM 
DA at 37°C.  At present, we chose to perform the experiments at room temperature, 
mimicking the conditions in which the TIRFM experiments were performed.  Rat striatal 
synaptosomes were treated with KRB or 10 µM DA for 1 min and surface DAT was 
measured by biotinylation.  As shown in Figure 2.7, there was a significant 30% increase 
in surface DAT as compared to vehicle following DA treatment that was blocked by 
simultaneous treatment with 1 μM of the DAT blocker, GBR12935.  In some 
experiments GBR12935 appeared to reduce surface DAT, but no significant difference 
between GBR12935 and KRB-treated cells was found.  Alternative statistical analysis 
using a one-way ANOVA which compared DA, GBR or DA + GBR treatments 
(excluding KRB alone) revealed a significant difference between DA v. GBR (p < 0.05) 
and DA v. DA + GBR (p < 0.01). 
PKC-β inhibition blocks the substrate-induced increase in DAT surface expression 
A previous report from our lab demonstrated that pretreatment with the specific 
PKC-β inhibitor, LY379196, attenuated AMPH-stimulated DA efflux in rat striatal slices 
(Johnson et al. 2005b).  We wished to examine whether PKC-β was affecting substrate-
induced DA efflux by altering rapid DAT trafficking to the surface.  To determine 
whether a PKC-β dependent effect was also occurring in the N2A cell system, TIRFM 
and biotinylation experiments were performed.  We found that these cells contain PKC-
β1 (data not shown).  Cells were pretreated for 5 min with KRH or 200 nM LY379196 
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and then treated with 5 µM AMPH or 10 µM DA in the presence of KRH or LY379196.  
As shown in Figure 2.8A, LY379196 slightly but significantly decreased the AMPH-
induced increase in surface DAT after two minutes of treatment.  Even though the zero 
time point in the LY + AMPH group appears lower than that of the AMPH alone group, 
none of the three zero time groups are significantly different from one another.  
LY379196 had similar effects on DA-induced increases of surface DAT although the 
blockade of the DA effect was more pronounced than with AMPH (Figure 2.8B).  These 
data are further validated with biotinylation experiments which show complete blockade 
of AMPH or DA-induced increases in surface DAT expression following pretreatment of 
LY379196 in DAT-N2A cells (Figure 2.8C).  Alternative statistical analysis using a one-
sample t-test revealed that AMPH-stimulated increases in DAT surface expression 
following KRH pretreatment were nearly significant (p = 0.051 as compared to 
hypothetical value of 1). Similarly DA-stimulated increases in DAT surface expression 
following KRH pretreatment were nearly significant (p = 0.052 as compared to 
hypothetical value of 1). However, LY379196 pretreatment blocked AMPH and DA-
stimulated increases (AMPH: p = 0.61; DA: p = 0.74 as compared to hypothetical value 
of 1). 
The blocking effect of LY379196 appeared more complete in the biotinylation 
experiments than in the TIRFM experiments.  This differential effect could indicate a 
delayed effect of the inhibitor when it is slowly perfused as opposed to being given as a 
bolus as in biotinylation. 
 We next examined whether PKC-β similarly affects substrate-induced DAT 
trafficking in rat synaptosomes.  Synaptosomes were treated with vehicle, 3 µM AMPH, 
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100 nM LY379196 or AMPH + LY379196 for 1 min and surface DAT expression was 
then measured using biotinylation (Figure 2.9A).  In the absence of LY379196, AMPH 
increased DAT surface expression 1.5 fold over vehicle but in the presence of drug, this 
effect was attenuated. LY379196 alone did not alter basal DAT surface expression 
indicating that there is a blockade of AMPH-induced DAT trafficking as opposed to a 
change in basal DAT trafficking.  To determine whether the inhibition of AMPH-induced 
DAT trafficking by PKC-β was sufficient to block AMPH-stimulated DA efflux, 
synaptosomes were pretreated with KRB, 3 µM AMPH, 100 nM LY379196 or AMPH + 
LY379196 for 1 min as described in the biotinylation experiment.  Synaptosomes were 
subsequently washed at 4°C to prevent trafficking and AMPH-induced DA efflux was 
measured (see Materials and Methods).  As we demonstrated previously (Johnson et al. 
2005a), a one minute pretreatment with AMPH alone (followed by washout) significantly 
enhanced AMPH-stimulated DA efflux (Figure 2.9B).  However, this enhanced efflux 
was blocked when AMPH and LY379196 were given simultaneously during the one 
minute pretreatment.  This demonstrates that the enhanced AMPH-stimulated DA efflux 
is likely due to increased DAT surface expression that is PKC-β dependent.  A one-
minute pretreatment of LY379196 alone followed by washout, did not block subsequent 
AMPH-stimulated DA efflux (Figure 2.9B). 
Discussion 
Using total internal reflection microscopy we have documented real-time 
trafficking of DAT to the cell surface in response to the substrates, AMPH and DA.  This 
is the first report to describe rapid trafficking of DAT in response to the physiological 
substrate DA independent of DA D2R stimulation.  To our knowledge, this is the first 
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report to demonstrate that rapid substrate-induced exocytosis of DAT is dependent upon 
the SNARE proteins, syntaxin 1A and VAMP/synaptobrevin. Moreover, the results 
obtained in the DAT-N2A cells are verified in rat synaptosomes using biotinylation.  We 
have also demonstrated the involvement of PKC-β in the rapid trafficking of DAT in both 
systems. 
Substrate-induced DAT trafficking to the plasmalemmal membrane occurred at 
times commensurate with activation of DAT by substrate.  Previously, using biotinylation 
of rat striatal synaptosomes, we demonstrated that incubation with AMPH increased DAT 
surface expression within 30 - 60 sec (Johnson et al. 2005b).  Functional significance of 
this rapid transit was established by an enhancement in AMPH-stimulated DA efflux, as 
shown again in this study.  We also find that pretreatment of synaptosomes with AMPH, 
followed by washing out of the drug, elicits an increase in [3H]DA uptake (Chen and 
Gnegy, in press).  Taken together, these results suggest a mechanism by which a DAT 
substrate rapidly recruits the transporter to the surface, increasing both substrate uptake 
and, in response to AMPH, efflux.  Upon continued exposure to substrate, the transporter 
undergoes internalization which reduces uptake of substrate.   
We sought to determine the mechanism of DAT trafficking towards the surface by 
visualizing the movement of GFP-DAT containing vesicles near the plasmalemmal 
membrane.  TIRFM provides real time resolution coupled with the ability to sensitively 
detect and analyze cytosol to plasmalemmal membrane movement of vesicles and 
granules.  TIRFM selectively illuminates the aqueous phase immediately adjacent to a 
glass interface with an exponentially decaying excitation (Axelrod 1981, Axelrod 2003).  
TIRFM has been used to discern tethering of GLUT4 containing vesicles to the rat 
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adipocyte membrane before fusion (Lizunov et al. 2005) as well as the multiple tethering 
states and significant motion of chromaffin granules immediately preceding exocytosis 
(Holz & Axelrod 2008).  
We were unable to detect fusion of individual puncta on the plasma membrane in 
these cells, which may be due to the diffuse pattern of DAT on the membrane, a low 
incorporation of DAT molecules into individual vesicles, or the small size of the 
individual vesicles.  The GABA transporter, GAT1, for example, is found in clear 
synaptic vesicles with a diameter of 50 nm (Deken et al. 2003).  Therefore, in order to 
determine whether the substrate-stimulated increase in DAT surface intensity was due to 
a fusion event, we used neurotoxins known to proteolyze SNARE proteins and inhibit 
exocytosis.  A role for vesicle fusion in the substrate-induced increase in GFP-DAT 
intensity is strongly suggested by the fact that neurotoxins affecting either a t-SNARE 
(syntaxin 1A) or a v-SNARE (VAMP/synaptobrevin) abolished the substrate-induced 
increase in fluorescence.  VAMP2 was detected as a component of small GAT-1-
containing vesicles in rat cortices (Deken et al. 2003), and the present study suggests it is 
also a component of DAT-containing vesicles.  In addition to playing an essential role in 
the docking and fusion of neurotransmitter-containing vesicles to the presynaptic 
membrane of neurons, syntaxin 1A regulates function and localization of transporters 
(Quick 2006).  Furthermore, we demonstrated that AMPH increases the binding of 
syntaxin 1A to DAT and that syntaxin 1A promotes AMPH-stimulated DA efflux in 
hDAT-expressing cells (Binda et al. 2008). 
Despite the sensitivity of TIRFM, we found distinct differences between TIRFM 
and biotinylation in quantitation of the degree of change in surface DAT following 
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substrate treatment.  Biotinylation showed AMPH and DA treatment to result in DAT 
surface expression that was 150 % and 250 % of control, respectively, whereas 
measurement by TIRFM showed ~112% of control for both substrates.  One major factor 
that likely contributes to this difference is that biotin has access only to transporter that is 
physically within the membrane and not to compartments that are continuous with the 
membrane (invaginations).  TIRFM, on the other hand, may detect DAT-containing 
compartments that reside immediately underneath the membrane and could contribute to 
background fluorescence.  The evanescent field of our TIRFM setup is ~100 nm and the 
intensity of fluorescence falls off exponentially with distance from the surface.  If the 
DAT-containing vesicles are similar in size to the ~50 nm GAT1-containing vesicles, 
background fluorescence could represent some DAT that is not integrally located in the 
plasmalemmal membrane.  Fluorescence of GFP-DAT >200 nm from the plasma 
membrane would be attenuated at least 90% so the source of the rapidly-trafficked DAT 
is likely within 100 nm of the membrane.  The increase in intensity following substrate, 
however, represents GFP-DAT that is moving closer to the membrane and would involve 
fusion events as suggested by the experiments with the neurotoxins.  The ‘background’ 
fluorescence detected in TIRFM could potentially represent the source of the DAT that 
moves to the surface following substrate stimulation.  More experiments are underway to 
determine where this rapidly translocated DAT is coming from within the cell. Carneiro 
& Blakely (2006) found that serotonin stimulation elicited a trafficking of the serotonin 
transporter, SERT, from cytoskeletal fractions to membrane fractions in platelets within 
30 min (Carneiro & Blakely 2006).  A similar, but more rapid, change in association 
could occur with DAT vesicles residing directly below the plasma membrane.  
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Other factors reported to increase surface DAT relatively rapidly are cocaine 
treatment and DA D2R activation.  Cocaine increased surface DAT in DAT 
overexpressed cells (Daws et al. 2002, Little et al. 2002).  An increase in DA uptake was 
seen after 5 min of 10 µM cocaine treatment (Daws et al. 2002).  Cocaine alone had no 
effect on DAT trafficking within our experimental time frame but blocked substrate-
mediated DAT trafficking in both synaptosomes and heterologous cells demonstrating 
that, in our system, substrate binding to DAT was required to elicit trafficking.  
Activation of D2Rs also regulate surface DAT and DA uptake (Meiergerd et al. 1993, 
Mayfield & Zahniser 2001).  Bolan et al. (2007) demonstrated a D2R-dependent increase 
in DAT surface expression in human DAT-N2A cells overexpressing the D2R following 
1 min of activation by the D2R agonist quinpirole.  Our human DAT-N2A cells were not 
overexpressing D2Rs but may contain low but active levels of endogenous D2 receptors.  
Our experiments clearly demonstrate, however, that the DA-induced increase in surface 
DAT in human DAT-N2A cells was not due to D2R activation since D2R overexpression 
in N2A cells did not change the DA-induced increase in DAT surface expression.  
Moreover, our experiments in rat striatal synaptosomes demonstrate that interaction of 
the substrate, DA, with DAT is required for the very rapid transport of DAT to the 
plasmalemmal membrane in a more physiological system.  However, more experiments 
in rat synaptosomes using specific D2R antagonists are needed to determine whether 
D2Rs are directly or indirectly involved.  
PKC appears to play an integral role in DAT trafficking.  Analogous to substrate 
treatment, a more prolonged exposure of synaptosomes or DAT-overexpressed 
heterologous cells to PKC-activating phorbol esters induces a down-regulation of DAT 
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(Melikian 2004, Sorkina et al. 2005).  However, evidence from our laboratory suggested 
that PKC could also enhance some DAT activities.  PKC inhibitors blocked AMPH-
stimulated DA efflux from rat striatum while phorbol esters themselves increased efflux 
(Kantor & Gnegy 1998, Cowell et al. 2000).  Johnson et al. (2005b) identified PKC-β as 
a PKC isozyme contributing to AMPH-stimulated DA efflux (Johnson et al. 2005b).  We 
have utilized the selective PKC-β inhibitor, LY379196, to demonstrate that PKC-β plays 
a role in the rapid substrate-induced trafficking in both DAT-N2A cells using TIRFM as 
well as biotinylation and in synaptosomes using biotinylation.  Further, using 
synaptosomes, we demonstrated functional consequences of the PKC-β effect in that the 
enhancement in AMPH-stimulated DA efflux following AMPH pretreatment was 
blocked by LY379196.  
Taken together, our results suggest that there are dual, biphasic regulations of 
DAT both by substrate and PKC activation.  Within seconds of interacting with DAT, 
substrates induce exocytosis of DAT-containing vesicles into the plasmalemmal 
membrane.  Substrate transport is likely required since experiments where sodium was 
removed failed to show increased DAT surface expression upon substrate exposure.  The 
movement of DAT to the surface is dependent upon PKC-β activation.  The source of 
DAT may be “readily releasable pools” in a subplasmalemmal membrane compartment 
that are primed for translocation into the plasmalemmal membrane during substrate 
stimulation.  Work by Schmidt et al. (1997) revealed a synaptic-like microvesicle 
compartment that is continuous with the plasmalemmal membrane in neuroendocrine 
cells (Schmidt et al. 1997).  
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 The rapid translocation of DAT-containing vesicles to the surface has functional 
consequences (Johnson et al. 2005a).  Longer treatment with substrate, or PKC activators, 
leads to internalization of the transporter, although AMPH-stimulated internalization may 
not require PKC (Boudanova et al. 2008).  It is possible that different isozymes of PKC 
could be responsible for the rapid transport and internalization of DAT, although it is 
likely that a ‘classical’ Ca2+-dependent PKC is also important for PKC-dependent 
internalization (Doolen & Zahniser 2002).  These studies are important for understanding 
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Figure 2.2.  Rapid AMPH-induced DAT trafficking to the plasma membrane - TIRFM analysis. 
Top, pseudocolored images of a representative GFP-DAT N2A cell perfused with KRH for 120 
sec followed by 5 μM amphetamine (AMPH) for 120 sec. Images show cell under KRH perfusion 
20 sec before addition of AMPH (-20 sec) and at 0, 60 and 120 sec after addition of 5 µM 
AMPH. Bottom, Image J quantitation of AMPH-induced increases in GFP-DAT pixel intensity.  
Cells were treated with KRH for 120 sec (20 sec prior to AMPH addition shown), followed by 
KRH (n = 5), 1 µM AMPH (n = 11) or 5 µM AMPH (n = 13) for 120 sec. Data are expressed as 
mean Arbitrary Fluorescent Units (AFU) normalized to 100 AFU. Dashed lines represent addition 
of KRH or AMPH at 0 sec and perfusion is switched back to KRH at 120 sec. Error bars 
represent SEM. p < 0.001 for dose and p < 0.0001 for time and interaction of dose and time: 
F(208, 2808) = 6.61 by 2-way ANOVA. In post-hoc Bonferonni testing, statistical significance (p 
< 0.05) is achieved from 60 sec to 138 sec with 1 µM AMPH, and from 42 sec to 180 sec with 5 
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Figure 2.3 Rapid DA-induced DAT trafficking to the plasma membrane - TIRFM analysis. Top, 
pseudocolored images of a representative GFP-DAT N2A cell perfused with KRH for 120 sec 
followed by 10 μM dopamine (DA) for 120 sec. Images show cell under KRH perfusion 20 sec 
before addition of DA (-20 sec) and at 0, 60 and 120 sec after addition of 10 µM DA. Bottom, 
Image J quantitation of DA-induced increases in GFP-DAT pixel intensity.  Cells were treated 
with KRH for 120 sec (20 sec prior to DA addition shown), followed by KRH (n = 5) or 10 µM 
DA (n = 14) for 120 sec. Data are expressed as mean Arbitrary Fluorescent Units (AFU) 
normalized to 100 AFU. Dashed lines represent addition of KRH or DA at 0 sec and perfusion is 
switched back to KRH at 120 sec. Error bars represent SEM. p < 0.01 for drug and p < 0.0001 for 
time and interaction of drug and time: F(104, 1976) = 6.73 by 2-way ANOVA. In post-hoc 
Bonferroni testing, statistical significance (p < 0.05) is achieved from 80 sec to 154 sec with 10 
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Figure 2.4 Cocaine blocks AMPH and DA-induced increases in GFP-DAT intensity in TIRFM. 
A, Cells were perfused for 2 min with KRH (white and black bars) or 30 µM cocaine (checkered 
bars) before addition of 5 µM amphetamine (AMPH, white bars, n = 5), 30 µM cocaine (black 
bars, n = 5) or 30 µM cocaine + 5 µM AMPH (checkered bars, n = 5) at t = 0. Data are expressed 
as mean arbitrary fluorescence units (AFU) and are normalized to 100 AFU (dashed line). Error 
bars represent SEM. Comparing across 3 drug groups, p < 0.0001 for drug and p < 0.05 for time 
by 2-way ANOVA. *p < 0.05 by post-hoc Bonferroni for 5 µM AMPH v. cocaine + AMPH at t = 
60 sec and *p < 0.001 for 5 µM AMPH v. cocaine + AMPH at t = 120 sec. Comparing time 
points within each group, #p < 0.001 by 2-way ANOVA - post hoc Bonferroni for 5 µM AMPH 
at t = 0 sec v. 120 sec. B, Cells were pretreated for 2 min with KRH (white and black bars) or 30 
µM cocaine (checkered bars) before addition of 10 µM dopamine (DA, white bars, n = 3), 30 µM 
cocaine (black bars, n = 5) or 30 µM cocaine + DA (checkered bars, n = 5) at t = 0. Comparing 
across 3 drug groups, p < 0.01 for drug and p < 0.05 for time by 2-way ANOVA. *p < 0.05 by 
post-hoc Bonferroni for 10 µM DA v. cocaine + DA at t = 120 sec. Comparing time points within 
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Figure 2.5 SNARE proteins regulate DA-induced DAT trafficking to the plasma membrane. N2A 
cells were co-transfected with GFP-DAT and empty vector (white bars, n = 13), the light chain of 
BoNT C (gray bars, n = 15) or the light chain of TeNT (black bars, n = 10). All cells were 
perfused for 2 min with KRH before addition of 10 µM DA for 2 min at t = 0. Data are expressed 
as mean arbitrary fluorescence units (AFU) and are normalized to 100 AFU (dashed line). Error 
bars represent SEM. p<0.05 for interaction, and p < 0.0001 for time and treatment by 2-way 
ANOVA. Post-hoc Bonferroni analysis: *p<0.01 for vector v. BoNT C at t = 120s, p<0.05 for 
vector v. TeNT at t = 60s and p<0.001 for vector v. TeNT at t = 120 s. Comparing time points 
within each group, #p<0.05 for vector at t = 0 v. 60 sec and p < 0.001 at t = 0 v. 120 s. There was 
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Figure 2.6 DA-induced DAT trafficking to the plasma membrane is D2R independent.  A, 
Quinpirole-induced [3H]DA uptake. [3H]DA uptake (5 min) was measured following a 15 min 
treatment with vehicle (KRH) or 10 µM quinpirole. Data are expressed as pmol DA per mg 
protein. Error bars represent SEM.  B, TIRFM - Image J quantitation of GFP-DAT N2A cells. 
Cells were pretreated for 2 min with KRH (white and black bars) or 10 µM sulpiride (checkered 
bars) before addition of 10 µM dopamine (DA, white bars, n = 15), 10 µM sulpiride (black bars, n 
= 5), or 10 µM sulpiride + 10 µM DA (checkered bars, n = 10) at  t = 0. Error bars represent 
SEM. Comparing across 3 drug groups, p < 0.0001 for drug and time by 2-way ANOVA. *p < 
0.001 by post-hoc Bonferroni for sulpiride + DA v. 10 µM sulpiride at 120 sec. No significant 
difference between 10 µM DA and sulpiride + DA treatment at any time point. Comparing time 
points within each group, #p <0.01 by 2-way ANOVA and post-hoc Bonferroni for 10 µM DA at 
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Table 2.1 Effect of D2R-overexpression in GFP-DAT N2A cells - TIRFM analysis. GFP-DAT 
N2A cells were transiently transfected with empty vector or D2R short DNA. Cells were perfused 
with 120 sec of KRH followed by 120 sec of 10 µM DA and finally 60 sec of KRH. The table 
depicts the mean arbitrary fluorescent units (AFU) at the time of drug addition (0 min), and 1 and 
2 min after drug addition. No statistical difference was found between the two curves by 2-way 





Figure 2.7 DA-induced DAT trafficking in rat striatal synaptosomes. Top, Representative 
western blot of biotinylated (surface) and lysate (total) of rat synaptosomes treated for 1 min with 
KRB, 10 µM dopamine (DA), 1 µM GBR12935 (GBR) or GBR12935 + DA (G+D). Bottom, 
Quantitation of biotinylation. Western blots were scanned and quantitated using Scion Image 
software. Data are expressed as fold KRB (OD biotin/ OD lysate). Error bars represent SEM. p < 
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2.8C, Biotinylation. Cells were pretreated with Vehicle or 200 nM LY379196 for 5 min followed 
by 1 min of KRH (n = 5), 3 µM amphetamine (AMPH, n = 5) or 10 µM dopamine (DA, n = 6). 
Data are expressed as biotin/lysate and normalized to the respective pretreatment control (Veh or 
LY). p<0.05 by one-way ANOVA for drug treatment. *p<0.05 by post hoc Bonferroni for Veh v. 
AMPH and Veh. v. DA in vehicle pretreated cells. There was no significant difference between 
Veh (mean = 1.00 ± 0.27 OD) and LY37 (mean = 1.15 ± 0.32) raw values as measured by 2-
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Figure 2.9 Role of PKC-ß in AMPH-induced DAT trafficking in rat synaptosomes.  A, 
Biotinylation of DAT in rat synaptosomes treated for one minute with vehicle (Veh, KRB), 3 µM 
amphetamine (AMPH), 100 nM LY379196 (LY) or AMPH + LY379196. Error bars represent 
SEM. *p < 0.05 by 1-way ANOVA, n = 3. Post-hoc Bonferroni analysis shows a significant 
difference between AMPH and Veh (p < 0.05) B, Synaptosomes were pretreated using same 
protocol as in A. Synaptosomes were washed 3 times at 4°C then further separated and treated 
with vehicle or AMPH. Data are expressed as AMPH-induced dopamine (DA) efflux (fold KRB): 
DA efflux with AMPH / DA efflux with KRB. Error bars represent SEM.*p < 0.01 by 1-way 
ANOVA, n = 4. Post-hoc Bonferroni analysis shows a significant difference of AMPH v. Veh ( p 
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Chapter III  
 
 
Rab 11 Regulates Constitutive Dopamine Transporter Trafficking and Function in 
N2A Neuroblastoma Cells 
 
Abstract 
The dopamine transporter (DAT) is a crucial regulator of dopaminergic 
neurotransmission which undergoes constitutive and substrate-mediated trafficking to and 
from the membrane. Although, considerable research has been done to elucidate the 
regulation of substrate-stimulated DAT trafficking, less is known about which trafficking 
proteins are involved in constitutive DAT trafficking. Rab proteins are GTPases known 
to regulate the trafficking of proteins to and from specific endocytic compartments. Rabs 
8 and 11, in particular, are involved in trafficking proteins from intracellular 
compartments to the plasma membrane. In this study, we sought to determine whether 
Rabs 8 and 11 would modulate DAT activity and trafficking in N2A neuroblastoma cells. 
We used Rab mutations known to confer constitutively active or dominant negative 
activity of these proteins to investigate the role of Rab activity in constitutive DAT 
trafficking and function. We found that constitutively active Rab 11 upregulates DAT 
function and surface expression while neither the constitutively active nor the dominant 
negative mutant of Rab 8 had any effect on DA uptake. Furthermore, 
immunofluorescence experiments revealed that dominant negative Rab 11 overexpression 
results in decreased surface DAT indicating a necessary function of Rab 11 in DAT 
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trafficking to the plasma membrane. These data show for the first time a functional role 
of Rab proteins in the constitutive recycling of DAT to the plasma membrane.  
 
Introduction 
The neurotransmitter dopamine (DA) can efficiently be removed from the 
synaptic cleft by reuptake into the nerve terminal by the dopamine transporter (DAT). 
DAT is an important regulator of dopaminergic neurotransmission as it is the key 
mechanism by which dopamine signaling is terminated (Amara & Kuhar 1993).  The 
DAT is a presynaptic plasma membrane protein with a predicted topology of twelve 
transmembrane domains with intracellular N and C tails (Giros & Caron 1993).  
Substantive evidence demonstrates dynamic regulation of DAT trafficking to and from 
the membrane which occurs constitutively and in the presence of DAT substrates (For 
review, see (Melikian 2004, Robertson et al. 2009)).  Constitutive DAT internalization 
was found to be clathrin-mediated in various heterologous cell lines including madin-
darby canine kidney (MDCK), human embryonic kidney (HEK) and porcine aortic 
endothelial (PAE) cells (Daniels & Amara 1999, Saunders et al. 2000, Sorkina et al. 
2005).  DAT undergoes constitutive internalization into early and recycling endosomes as 
indicated by its co-localization with endosomal markers (Melikian & Buckley 1999, 
Sorkina et al. 2003, Sorkina et al. 2005).  Rab proteins regulate trafficking of proteins to 
specific endosomal compartments and are thought to mediate tethering or delivery to the 
plasma membrane (Zerial & McBride 2001).  Rab 8 localizes to the trans golgi network 
(TGN) and regulates the trafficking of proteins from the TGN to the plasma membrane 
(Ang et al. 2003).  Rab 11 predominantly localizes to the pericentriolar recycling 
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endosomes and is thought to regulate trafficking of proteins from the recycling 
endosomes to the plasma membrane (Sonnichsen et al. 2000, Stenmark & Olkkonen 
2001, Zerial & McBride 2001).  The DAT recycles into the endocytic recycling 
compartment (Melikian & Buckley 1999).  Loder and Melikian (Loder & Melikian 2003) 
demonstrated that DAT proteins recycle into Rab 5 containing endosomes in PC12 cells. 
Treatment with the PKC activator phorbol myristate acetate or the DAT substrate 
amphetamine (AMPH) for 1-2 hours induced DAT internalization into Rab 11- and Rab 
5-containing compartments (Sorkina et al. 2003).  Notably, the authors in that study 
found a small amount of DAT co-localized in Rab 11-containing endosomes in the 
absence of treatment indicating constitutive trafficking to these endosomes.  Furthermore 
Rab proteins have been implicated in trafficking of other transporters such as the insulin-
sensitive glucose transporter GLUT4 (Zaid et al. 2008).  The role of Rab protein function 
in DAT trafficking and activity has not been investigated. In the present study, we 
utilized constitutively active (CA, GTP-bound) or dominant negative (DN, GDP-bound) 
mutants of Rab to investigate their role in DAT function.  Here we show in N2A 
neuroblastoma cells that a constitutively active form of Rab 11 upregulates DAT activity 
and trafficking to the surface while the dominant negative decreases DAT surface 
expression.  These data indicate a sufficient and necessary role of Rab 11 in constitutive 
DAT trafficking.    
Methods 
GFP-Rab DAT-N2A cells 
Rab GTPase DNA constructs with single point mutations known to confer either a 
GDP bound/dominant negative state or a GTP-bound/constitutively active state were 
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generated.  N2A neuroblastoma cells stably expressing human DAT were transiently 
transfected with the constitutively active mutants of Rab 8 (Q67L) and 11 (Q70L) or the 
dominant negative mutant of Rab 8 (T22N) and Rab 11 (S25N) using Lipofectamine-
PLUS reagent kit.  These mutants have previously been described (Gerges et al. 2004). 
All Rab proteins contain an N-terminal Green Fluorescent Protein (GFP) tag for labeling. 
GFP-Rab fusion proteins correctly localize to membranes (Ang et al. 2003, Sonnichsen et 
al. 2000).  As a transfection control, cells were transiently transfected with the GFP-
vector alone.   
[3H]dopamine uptake assay  
Twenty-four hours after transfection, cells were plated in quadruplicate (4 
wells/transfection) onto coated 24-well plates and incubated for another 24 hours.  Cells 
were washed twice with Krebs Ringers Hepes (KRH) buffer composed of (in mM): 25 
HEPES, 125 NaCl, 4.8 KCl, 1.2 KH2PO4, 1.3 CaCl2, 1.2 MgSO4, and 5.6 glucose.  KRH 
was removed and uptake was initiated with the addition of [3H]dopamine (10 nM, Perkin 
Elmer) + unlabeled dopamine in KRH at 25ºC in the presence or absence of the DAT 
blocker 10 µM GBR12935 to determine non-specific binding.  Five minutes after 
treatment, cells were rapidly washed twice with KRH and 1% sodium dodecyl sulfate 
was added to solubilize cells.  Lysed cells were collected and scintillation fluid was 
added to the vials before radioactive counting on a Beckman Liquid Scintillation counter.  
One well per transfection was assayed for protein content (Bio-Rad DC protein assay kit) 
and data were plotted as pmol DA uptake/mg protein.  Specific uptake was determined in 
the presence and absence of the DAT inhibitor GBR12935 (10 µM).  
[3H]WIN35428 binding assay 
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Cells were plated as described for the [3H]dopamine uptake assay.  Cells were 
washed twice with 4°C KRH to stop constitutive DAT trafficking.  [3H]WIN35428 
binding was initiated by the addition of 4 nM [3H]WIN35428 + 70 nM unlabeled 2 beta-
carbomethoxy-3- beta-(4-fluorophenyl)-N-methyltropane in 4°C KRH buffer in the 
presence or absence of 10 µM GBR12935 to determine non-specific binding.  Thirty 
minutes after [3H]WIN35428 treatment, cells were rapidly washed two times with cold 
KRH.  Cells were counted for radioactivity as in the [3H]dopamine uptake assay.  One 
well per transfection was assayed for protein content and data were plotted as pmol 
[3H]WIN35428 bound/mg protein.  
Immuno-fluorescence experiments  
N2A cells were transiently co-transfected with DAT containing a hemagglutinin 
(HA)-epitope in the extracellular loop (generously supplied by Dr. Jonathan Javitch, 
Columbia University) and GFP vector, GFP-Rab 11CA, or GFP-Rab 11DN.  Twenty-
four hours after transfection cells were replated onto coated glass coverslips and 
incubated at 37°C for 24 hours.  Immuno-fluorescence assays were carried out at ~10-
15ºC.  Cells were washed twice with phosphate buffered saline supplemented with 
calcium and magnesium (PBS/Ca/Mg) and blocked with 2% normal goat serum. Surface 
labeling of DAT was achieved by incubating cells with 1:250 anti-HA (Covance) 
followed by 1:250 of secondary goat α-mouse AF594 (Invitrogen).  In some cases, cells 
were permeabilized to determine total DAT content using 0.1% triton X-100 in 
PBS/Ca/Mg followed by anti-DAT (MAB369: Millipore Biomedical Research) or anti-
HA and corresponding secondary antibody conjugated to AF594 (Goat anti-mouse) or 
AF647 (Goat anti-rat, Invitrogen).  Cells were mounted onto glass slides using ProLong 
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Gold anti-fade reagent (Invitrogen).  Cells were imaged on an Olympus FluoView 500 
confocal microscope.  Sequential scans were taken to prevent overlap of laser signal. Z-
slices of cells were compressed and quantified using Image J software (NIH). 
Background was subtracted from each image. A total of 28 cells (28 for surface, 23 for 
total) were analyzed from three separate cultures.  
Results 
Rab 11CA increases [3H]DA uptake 
Both Rab 11 and Rab 8 have been shown to facilitate trafficking of proteins from 
intracellular compartments to the plasma membrane.  If these proteins affect constitutive 
DAT trafficking and thus surface DAT, we would expect a change in DAT function 
reflected in the amount of [3H]dopamine uptake.  In order to determine whether Rab 11 
or Rab 8 regulates DAT function, N2A-human DAT cells were overexpressed with the 
CA or DN forms of GFP tagged Rab 11 and 8.  As shown in Figure 3.1A, overexpression 
of GFP-Rab 11CA increased [3H]dopamine uptake to 127% of GFP vector control 
(p<0.01 by one-way ANOVA).  Although GFP-Rab 11DN slightly decreased DA uptake 
to 84 ± 7% of control, there was no statistical significance when compared to GFP vector 
alone.  Alternative statistical analysis using an unpaired t-test comparing Rab 11CA and 
Rab 11DN transfected cells revealed a significant difference between these two groups (p 
< 0.01).  Transfection of either the constitutively active or dominant negative form of 
GFP-Rab 8 had no effect on [3H]dopamine uptake as shown in Figure 3.1B.   
Rab 11CA increases [3H]WIN35428 binding 
To determine whether this increase in function with GFP-Rab11CA was due to 
more DAT on the surface, [3H]WIN35428 binding experiments were performed.  WIN 
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35428 has been shown to measure DAT surface expression in numerous experiments and  
is presumed to specifically label plasma membrane DAT (Chen et al. 2004, Li & Reith 
1999).  Figure 3.2 demonstrates an increase in [3H]WIN35428 binding in cells transiently 
expressing GFP-Rab 11CA to 137% of control (GFP vector alone), p<0.05 by one-way 
ANOVA.  No significant difference was found between GFP vector alone- and GFP-Rab 
11DN-transfected cells.  Alternative statistical analysis using an unpaired t-test 
comparing Rab 11CA and Rab 11DN transfected cells revealed a nearly significant 
difference between these two groups (p = 0.054).  Changes in [3H]dopamine uptake and 
[3H]WIN35428 binding will only be reflected when there is a large effect because cells 
which do not contain overexpressed Rab 11 (i.e. cells which did not take up DNA) will 
also be measured in these assays.  This may result in an under-representation of the effect 
that occurs in transfected cells.  
Rab 11CA increases DAT surface expression 
In order to measure effects of Rab 11 on DAT surface expression in individual 
cells, we performed immunofluorescence experiments.  These experiments enabled us to 
exclude cells which did not contain a sufficient (visible) amount of GFP, GFP-Rab 11CA 
or GFP-Rab 11DN.  In order to visualize and quantify surface DAT, a human DAT 
construct containing an HA tag in the extracellular loop was used.  The HA-DAT 
construct used in these experiments has previously been described and has comparable 
function to wild-type DAT (Sorkina et al. 2006).  Non-permeabilized cells were reacted 
with anti-HA to label surface DAT followed by a secondary antibody conjugated to a 
fluorescent (AF594, red) tag.  To ensure that changes in surface DAT did not reflect total 
amounts of DAT within the cell, some cells were permeabilized and reacted with either 
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an anti-DAT antibody that binds to the N-terminal tail of DAT or anti-HA.  Cells that 
were permeabilized and reacted with anti-HA for total DAT were not previously exposed 
to antibody.  The cells were then reacted with a secondary antibody conjugated to a 
fluorescent tag. Figure 3A shows the surface labeling (anti-HA) of representative cells 
transfected with GFP-vector (left panel) or GFP-Rab 11CA (right panel).  Cells 
transfected with GFP-Rab 11CA show increased surface DAT fluorescence intensity as 
compared to those transfected with GFP vector alone.  GFP-Rab 11CA transfected cells 
had a 2-fold increase in DAT surface expression as compared to GFP vector alone (GFP 
= 31 ± 3.1%, 11CA = 67 ± 8.7 %, Figure 3.3B).  
Rab 11DN reduces DAT surface expression 
  GFP-Rab 11DN transfected cells demonstrated significantly decreased surface 
staining as compared to GFP-vector alone as shown in figure 4.  Figure 4A shows 
representative cells co-transfected with HA-DAT and GFP vector (left) or GFP-Rab 
11DN (right).  Quantification of surface DAT images demonstrates a significant decrease 
in surface labeling in GFP-Rab11DN transfected cells compared to GFP vector 
transfected cells (GFP = 38 ± 3.3%, 11DN = 23 ± 4.5%, Figure 3.4B).  Analysis of cells 
permeabilized and stained for total DAT revealed lower but statistically insignificant total 
DAT levels (optical density measurement) for 11CA and 11DN as compared to GFP; p = 
0.14, by unpaired t-test for 11CA (303 ± 24, n = 4) v. GFP (419 ± 59, n = 5) and p = 0.15 
for 11DN (363 ± 77, n = 8) v. GFP (612 ± 160, n = 6).  
Discussion 
This paper describes the novel finding that Rab 11 activity regulates DAT 
function and trafficking.  By utilizing mutants of Rab GTPase proteins, we demonstrated 
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that DAT trafficking and function was increased in cells expressing a constitutively 
active form of Rab 11.  For Rab 11CA transfected cells, [3H]WIN35428 binding and 
[3H]dopamine uptake both increased to a similar degree (127 ± 9.7% of GFP vector for 
[3H]dopamine uptake and 136.6 ± 15% of GFP vector for [3H]WIN35428 binding).  
When looking at individual cells to ensure that all cells analyzed contained GFP-Rab 11 
DNA, we found even greater effects with GFP-Rab 11CA as compared to GFP vector 
alone (Figure 3).  The difference in magnitude of DAT surface expression as measured 
by [3H]WIN35428 binding versus immuno-fluorescence experiments is likely because in 
[3H]WIN35428 binding experiments, the measurement represents a net effect of 
untransfected cells and Rab 11-transfected cells where the untransfected cells likely 
dampen the effect of Rab 11CA-transfected cells.  Although we did not see an effect of 
GFP-Rab 11DN in the [3H]dopamine uptake or [3H]WIN35428 binding assays, when 
measuring individual cell effects, we found decreased DAT surface expression in GFP-
Rab 11DN-transfected cells as compared to GFP vector-transfected cells (Figure 3.4). 
While Rab 8 had no effect on [3H]dopamine uptake, it should be noted that we can’t rule 
out a role of Rab 8 in DAT trafficking as immunofluorescence experiments with Rab 8 
were not performed. 
These data demonstrate a specific role for Rab 11 to regulate trafficking of DAT 
to the plasma membrane.  Based on co-fractionation studies in DAT-PC12 cells, the 
predominant location of intracellular DAT at steady state is in the pericentriolar recycling 
endosome (Melikian & Buckley 1999), which is also the main location of Rab 11 (Zerial 
& McBride 2001).  The most parsimonious explanation of our data, therefore, is that 
upregulation of Rab11 increased trafficking to the membrane of DAT which originated 
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from these recycling endosomes.  Our data support the finding that intracellular DAT is 
localized to Rab 11-containing vesicles constitutively and in response to DAT substrates 
(Sorkina et al. 2003). 
 Historically, proteins known to be sorted by Rabs have been receptors such as 
transferrin receptor, α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) 
receptor and epidermal growth factor receptor (Ceresa 2006, Mohrmann & van der Sluijs 
1999, Gerges et al. 2004).  However, increasing evidence has showed that channels and 
transporters are also trafficked through Rab dependent pathways (Ishikura et al. 2008, 
McEwen et al. 2007).  Since endosomal compartments can be somewhat fluid, it can be 
difficult to distinguish in which compartments a protein resides.  Both Rabs 11 and 8 
have been localized to the TGN as well as the pericentriolar recycling endosome (Ang et 
al. 2003, Sonnichsen et al. 2000, Zerial & McBride 2001) however Rab 8 is thought to be 
the predominant mediator of protein trafficking from the TGN to the plasma membrane 
(Zerial & McBride 2001).  Differentiating the role of Rab 11 versus Rab 8 in affecting 
DAT function helps determine the specific compartment to which DAT is localized.  
Numerous studies have focused on DAT internalization, usually following PKC 
activation or substrate treatment, while fewer studies demonstrate trafficking proteins 
necessary for constitutive DAT recycling.  The mechanism of neurotransmitter 
transporter fusion to the plasma membrane has been a strong research area of interest.  It 
is now evident that soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE) proteins are important regulators of monoamine transporter trafficking (Quick 
2006).  The SNARE protein syntaxin 1A has been shown to interact with the N-terminus 
of DAT and regulate its activity (Binda et al. 2008, Lee et al. 2004).  Furthermore, in the 
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norepinephrine transporter (NET), syntaxin has been demonstrated to regulate clearance 
capacity of norepinephrine in a calcium and PKC-dependent manner (Sung et al. 2003, 
Sung & Blakely 2007).  We found that syntaxin 1A is important for the substrate-
stimulated translocation of DAT to the plasma membrane (Furman et al. 2009).  It is 
generally believed that SNARE proteins are necessary for the fusion of vesicles to the 
plasma membrane but that other proteins such as Rabs may be necessary to mediate the 
delivery and tethering of vesicles to allow for fusion.  A potential role for Rab 11 could 
be to assist in fusion of DAT-containing vesicles to the plasma membrane by delivery or 
tethering.  Since Rab 11CA mimics the rapid trafficking of DAT to the surface upon 
amphetamine (AMPH) treatment (Furman et al. 2009), it is tempting to speculate that 
AMPH may act through a Rab-11 dependent pathway to traffic DAT from the recycling 
endosome to the plasma membrane.  A similar mechanism has been demonstrated with 
another transporter GLUT4 which requires Rab 11 for transport from the endocytic 
recycling compartment to the GLUT4 storage vesicles which are primed for GLUT4 
translocation to the plasma membrane (Ishikura et al. 2008).  
However, it remains to be determined whether Rab 11 functions to increase the rate of 
DAT exocytosis or slow down the rate of endocytosis.  Also, further studies are needed to 
determine whether Rab 11 directly interacts with DAT or whether there is an indirect 
interaction via a Rab 11 binding protein.  
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Figures  
Figure 3.1 Rab 11CA increases [3H]DA uptake. A, DAT-N2A cells were transiently transfected 
with GFP-vector (GFP, n = 17), GFP-Rab 11CA (11CA, n = 9) or GFP-Rab 11DN (11DN, n = 
14) and assayed for [3H]DA uptake (specific activity = 10 nM). p<0.0001 by one-way ANOVA. 
Post hoc Bonferroni analysis shows a significant difference between GFP and11CA (**p<0.01) 
and between 11CA and 11DN (***p<0.0001, stars not shown) B, Cells were transiently 
transfected with GFP-vector (GFP, n = 10), GFP-Rab 8CA (8CA, n = 5) or GFP-Rab 8DN (8DN, 
n = 6). No significant difference by one-way ANOVA between any groups was seen (p = 0.49). 
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Figure 3.2 Rab 11CA increases [3H]WIN35428 binding. A, DAT-N2A cells were transiently 
transfected with GFP-vector (GFP, n = 5), GFP-Rab 11CA (11CA, n = 5) or GFP-Rab 11DN 
(11DN, n = 5) and assayed for [3H]WIN35428 binding (specific activity = 4 nM). p <0.05 by one-
way ANOVA. Post hoc Bonferroni analysis shows a significant difference between GFP and 
11CA (*p <0.05). Data are plotted as pmol [3H]WIN35428 bound per mg protein as a percentage 
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Syntaxin 1A regulates basal and stimulated dopamine transporter surface 
expression and function in rat synaptosomes and DAT-N2A cells 
 
Abstract 
The dopamine transporter (DAT) is a critical regulator of dopaminergic 
neurotransmission. DAT facilitates the reuptake of dopamine (DA) from the extracellular 
space thereby maintaining proper storage of DA into vesicles and terminating DA 
signaling.  Regulation of DAT function is achieved through trafficking and direct or 
indirect protein-protein interactions.  The psychostimulant amphetamine (AMPH) is a 
substrate for DAT which stimulates DA efflux.  On a time scale commensurate with its 
effects on DA efflux (60 sec), AMPH increases trafficking of DAT towards the surface in 
both DAT-N2A cells and rat striatal synaptosomes.  The AMPH-stimulated rapid 
trafficking of DAT is functionally expressed as an increase in [3H]DA uptake and an 
increase in AMPH-stimulated DA efflux.   Syntaxin 1A (SYN1A) is a soluble N-
ethylmaleimide sensitive factor attachment protein receptor (SNARE) protein that 
directly binds to the N-terminus of DAT and regulates its activity.  AMPH increases the 
DAT/SYN1A interaction in mouse synaptosomes and DAT-HEK cells overexpressing 
SYN1A.  The goal of the current study was to determine the role of the DAT/SYN1A 
interaction on basal and AMPH-stimulated DAT activity and rapid trafficking.    
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Botulinum neurotoxin C (BoNT/C) was used to assess the role of SYN1A in basal 
[3H]DA uptake, DAT surface expression, and AMPH-stimulated DA efflux in 
synaptosomes.  Basal and AMPH-stimulated DAT/SYN1A interactions were measured 
by immuno-precipitation in rat synaptosomes and DAT-N2A cells which endogenously 
express SYN1A.  In addition, an ‘open’ form mutant of SYN1A was used to determine to 
which form of SYN1A DAT binds. 
Our results indicate that cleavage of SYN1A by BoNT/C reduced basal DAT 
function, AMPH-stimulated DA efflux and DAT surface expression in synaptosomes to 
approximately 50% of control.  AMPH increased the DAT/SYN1A interaction in rat 
synaptosomes and DAT-N2A cells to approximately 2-fold over control after only 30 
seconds of treatment which correlated with the 2-fold increase over control in rapid DAT 
trafficking stimulated by AMPH in these systems.  In contrast, following 5 min of AMPH 
treatment, surface DAT was at control levels and we saw no change in DAT/SYN1A 
interaction.  In addition, we found that DAT is able to bind to an open form of SYN1A to 
the same degree as wild-type SYN1A.  Therefore, our preliminary data suggest that 
AMPH increases DAT/SYN1A interactions through a trafficking dependent mechanism.  
Further studies are needed to determine whether AMPH can affect DAT/SYN interaction 
in a non-trafficking environment.    
Introduction 
The dopamine signaling pathway is involved in the regulation of movement and 
cognition as well as motivation and pleasure (Giros & Caron 1993, Iversen 1971). The 
A9 and A10 dopamine pathways are thought to be the predominant ‘reward’ pathways 
that are activated during natural rewards such as food and sex as well as ‘unnatural’ 
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rewards such as psychostimulant abuse (Koob 2009).  The dopamine transporter (DAT) 
is crucial in terminating dopamine (DA) signaling by removing extracellular DA from the 
synapse following exocytosis.  DAT is a twelve transmembrane spanning protein 
belonging to the SLC6 class which includes the norepinephrine (NET) and serotonin 
transporters (SERT) (Amara & Kuhar 1993).  In addition to the natural substrate DA, the 
psychostimulant amphetamine (AMPH) is also a substrate and is taken up into the nerve 
terminal by DAT. Once taken up, AMPH can stimulate a reversal of the DAT and 
promote DA efflux into the extracellular space.  
DAT as well as other neurotransmitter transporters traffics dynamically in a 
constitutive manner and in response to stimuli such as substrates (Kahlig & Galli 2003, 
Melikian 2004).  Recently, researchers have focused on elucidating signaling 
mechanisms involved in transporter trafficking to and from the membrane.  The cytosolic 
N-terminus of DAT is important for translocation to the plasma membrane or retention at 
the plasma membrane while the C-terminus of DAT is important for constitutive and 
PKC-mediated endocytosis of DAT (Holton et al. 2005, Sorkina et al. 2005, Boudanova 
et al. 2008, Sorkina et al. 2009).  The N-terminus is also the site of many protein-protein 
interactions that can regulate DAT surface expression and activity (Torres 2006).  
The SNARE (soluble N-ethylmaleimide associated protein receptor) protein 
syntaxin 1A (SYN1A) is known to bind directly to the N-terminus of DAT (Binda et al. 
2008, Lee et al. 2004) and modulate AMPH-stimulated DA efflux through DAT.  
Additionally, rapid substrate induced exocytosis of DAT is blocked by botulinum 
neurotoxin C (BoNT/C) which cleaves SYN1A (Furman et al. 2009).  Several studies 
investigating the role of SYN1A in NET demonstrate that SYN1A directly binds to the 
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N-terminus of NET and regulates constitutive NE uptake (Sung et al. 2003).  Syn1A 
modulation of NET function and trafficking is regulated by protein kinase C (PKC) 
activity as well as calcium levels (Sung et al. 2003, Sung & Blakely 2007).  Syntaxin 1A 
interaction with other monoamine transporters including SERT, NET and GAT has also 
been shown (Quick 2006).  Our lab demonstrated that cleavage of either the t-SNARE 
SYN1A by BoNT/C or the v-SNARE protein VAMP-2 by tetanus neurotoxin abolished 
rapid substrate-stimulated DAT trafficking to the plasma membrane (Furman et al. 2009). 
In this study, we sought to investigate the mechanism of SYN1A on DAT 
function and surface expression in basal and AMPH-stimulated conditions.  We found 
that SYN1A is necessary for maintenance of proper DAT function and trafficking under 
basal conditions and that the AMPH-stimulated DAT/SYN1A interaction may be 
trafficking dependent.  
 
Methods 
[3H]DA uptake following BoNT/C pretreatment 
Rat synaptosomes were prepared as described previously (Johnson et al. 2005b) 
and were incubated for 90 min at 37°C in the presence or absence of 200 nM BoNT/C.  
DAT-mediated DA uptake was measured by treating samples with varying concentrations 
(0.3 – 3 µM) of [3H]DA (specific activity 23.5 Ci/mmol; Perkin Elmer) for 3 min at 
37°C. Nonspecific DA uptake was measured in the presence of 30 µM cocaine.  
Following incubation, synaptosomes were filtered onto glass fiber C Whatman filters and 
washed three times with excess cold PBS.  Filters were dried and counted on a Beckman 
scintillation counter.  
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Biotinylation of rat synaptosomes following BoNT/C pretreatment 
Rat synaptosomes were prepared and treated with BoNT/C as described above. 
Synaptosomes were washed 3 times in 4°C PBS/Ca/Mg and biotinylation experiments 
were performed as previously described with minor changes (Furman et al. 2009).  
Briefly, synaptosomes were treated with 1.5 mg/ml EZ link sulfo-NHS-SS-Biotin (Pierce, 
Rockford IL) for 1 hr at 4°C.  The biotinylation reaction was stopped by treatment of 100 
mM glycine, followed by 2 additional washes with 100 mM glycine in PBS/Ca/Mg.  
Synaptosomes were lysed in radioimmuno-precipitation assay buffer composed of: 25 
mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% SDS and 
centrifuged at high speed to rid of insoluble matter.  Lysate was reacted with saturating 
amounts of streptavidin beads (Pierce, Rockford IL).  Streptavidin beads were washed 3 
times and protein was eluted in a sample buffer containing fresh dithiothreitol.  
Biotinylated (surface) and lysate (total) fractions were resolved by western blot analysis 
using a DAT antibody (MAB16, generously supplied by Dr. Roxanne Vaughan, 
University of North Dakota).  Protein was detected using pico enhanced 
chemiluminescence reagents (Pierce) and the optical density of bands was quantitated 
using Scion Image Software.  
AMPH stimulated DA release following BoNT/C pretreatment  
Female Holtzman rats (~200 - 250g) were sacrificed and rat striatal slices were 
prepared by hand.  Tissue was incubated for 90 min at 37°C in the absence or presence of 
200 nM BoNT/C.  Samples were loaded onto a perfusion system (Brandel SF-12; Brandel 
Inc., Gaithersburg, MD) and washed with oxygenated Krebs Ringer Buffer (KRB) 
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composed of (in mM):  145 NaCl, 24.9 NaHCO3, 2.7 KCl 1.2 KH2PO4, 1.2 CaCl2, 1.0 
MgCl2, 10 glucose, 0.05 ascorbic acid, and 0.05 pargyline.  Perfusate was collected into 
vials containing a final concentration of 0.1 N HClO4, 50 µM ethylenediamine 
tetraacetate, and 10 nM 2-aminophenol as an internal standard.  Each fraction was 
collected for 2 min (0.4 ml/min) and a challenge of 3 µM AMPH at fraction number 5 
was applied to measure AMPH-stimulated DA efflux and sample collections were 
continued for 24 additional minutes.  DA was measured by high performance liquid 
chromatography with electrochemical detection (ESA biosciences).  
Cell culture 
Stable human DAT N2A cells were a gift from Dr. Karley Little (University).  
Cells were maintained in OPTI-mem (Invitrogen) supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin.  
Immuno-precipitation of DAT in synaptosomes and N2A cells   
Rat striatal synaptosomes (as described above) or DAT-N2A cells were treated 
with 10 µM AMPH for 30 sec and/or 5 min at 37°C in KRB (synaptosomes) or Krebs-
Ringer HEPES (KRH, cells) composed of (in mM): 25 HEPES, 125 NaCl, 4.8 KCl, 
1.2KH2PO4, 1.3 CaCl2, 1.2 MgSO4, and 5.6 glucose.  The reaction was stopped by 
addition of ice-cold buffer and samples were washed to deplete AMPH.  Samples were 
then lysed in RIPAE buffer (synaptosomes) or solubilization buffer (DAT-N2A cells) 
composed of (in mM): 25 Tris, 150 NaCl, 1 ethylene-diamine-tetraacetic acid (EDTA), 5 
N-ethylmalemide, phenylmethylsulfonyl fluoride and 1% triton-X 100 containing 
protease inhibitors (Roche).  Equal amounts of lysate were loaded onto protein A 
sepharose (PAS) beads (Sigma) and rotated for 3 hours to preclear lysate samples.  
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Precleared lysate samples were then incubated overnight with a DAT antibody 
(synaptosomes - purified DAT ab; N2A samples – AB5802 (Chemicon)).  Samples were 
then added to PAS beads and rotated for an additional 3 hours to immuno-precipitate 
DAT.  PAS beads containing DAT were washed 3 times in buffer (RIPAE for 
synaptosomes; solubilization buffer for N2A cells) and eluted in sample buffer composed 
of (in mM) 250 Tris pH 6.8, 25 EDTA, 10 % sodium dodecyl sulfate, 25 % sucrose, 0.5 
% bromophenol blue and supplemented with 100 dithiothreitol.  Western blot analysis 
was performed using a monoclonal anti-syntaxin antibody (Sigma).  A monoclonal anti-
DAT antibody (MAB369, Chemicon) was used to verify pull-down of DAT.  Protein was 
detected using enhanced chemiluminescence detection (Pierce).  Western blot bands were 
quantified using Scion Image software.  
Immuno-precipitation of DAT in DAT-N2A cells transiently transfected with cyan 
fluorescent protein (CFP)-syntaxin 
DAT N2A cells were transiently transfected with wild-type CFP-SYN1A or 
‘open’ CFP-SYN1A using the calcium-phosphate method.  Forty-eight hours after 
transfection cells were washed twice in PBS and removed from the plate.  Cells were 
lysed in solubilization buffer containing fresh protease inhibitor.  Immuno-precipitation 
experiments were performed as described above.  
Confocal microscopy 
Cells transfected with wild-type CFP-SYN1A or open CFP-SYN1A were plated 
onto glass bottom dishes (mat-tek) and imaged on an Olympus FluoView 500 confocal 
microscope using a 405 nm laser.  
Statistics 
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Graph Pad Prism 5 was used for statistical analysis.  Values for the kinetic 
constants, Km and Vmax, for the hDAT and mutant DAT constructs were determined by 
nonlinear regression analysis of the mean values for each mutant using GraphPad Prism 
version 5.  Statistical significance was determined using GraphPad Prism version 5 using 
an F-test by comparing fits in which selected values were constrained to be equal or were 
allowed to differ.  The null hypothesis was that the best fit parameter for the value did not 
differ.  A conclusion of statistical significance represents a rejection of the null 
hypothesis and indicates a difference between designated values.   
Results 
BoNT/C reduces [3H]DA uptake and DAT surface expression in rat synaptosomes  
To determine whether SYN1A regulates basal DAT function and surface 
expression, we treated synaptosomes with BoNT/C to cleave SYN1A. As shown in 
Figure 1, treatment with BoNT/C significantly reduced [3H]DA uptake in rat striatal 
synaptosomes as compared to KRB treated synaptosomes  (Fig 1A; unpublished data – 
Myung Kim).  The maximal DA uptake velocity (Vmax) was significantly lower (p < 
0.001 by unpaired t-test) in BoNT/C treated synaptosomes (7.89 ± 0.31 pmol DA/mg 
protein/min) v. control-KRB (15.5 ± 0.55 pmol DA/mg protein/min).  In addition, Km 
values of BoNT/C treated cells were also significantly different from control (p < 0.01 by 
unpaired t-test for BoNT/C treated - 0.137 ± 0.03 µM v. control – 0.408 ± 0.08 µM).  To 
determine whether the change in [3H]DA uptake was due to surface expression changes, 
biotinylation experiments were performed. Biotinylation experiments revealed a 
reduction in DAT surface expression in synaptosomes pretreated with BoNT/C to 47% of 
control (Fig 4.1B; unpublished data – Myung Kim).  Alternative statistical analysis using 
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a one-sample t-test revealed a significant decrease in BoNT/C treated cells (p < 0.01 as 
compared to a hypothetical value of 100). 
BoNT/C reduces AMPH-stimulated DA efflux in rat striatal slices 
Overexpression of SYN1A in DAT N2A cells resulted in increased AMPH-
stimulated DA efflux (Binda et al. 2008).  To determine the effect of endogenous SYN1A 
on AMPH-stimulated DA efflux, we used BoNT/C treated synaptosomes.  AMPH-
stimulated DA efflux was reduced in BoNT/C treated synaptosomes as compared to 
KRB-treated synaptosomes (Fig 4.2; unpublished data – Myung Kim).  
AMPH stimulates DAT/SYN interactions    
It has previously been demonstrated that AMPH stimulates the DAT/SYN1A 
interaction in mouse synaptosomes and DAT-HEK cells transiently over-expressing 
SYN1A after 5 minutes of treatment (Binda et al. 2008).  To determine whether AMPH 
influences DAT and SYN1A interaction with times commensurate with rapid DAT 
trafficking, rat synaptosomes were treated in the absence or presence of 10 µM AMPH 
for 30 seconds.  As shown in Figure 3A, AMPH significantly increased the DAT/SYN1A 
interaction in rat synaptosomes after 30 seconds of treatment (Figure 4.3A; unpublished 
data – Myung Kim).  Alternative statistical analysis using a one-sample t-test revealed a 
significant increase in AMPH-pretreated synaptosomes (p < 0.01 as compared to a 
hypothetical value of 1).  Neuroblastoma (N2A) cells endogenously express SYN1A as 
well as other SNARE proteins such as SNAP25 (data not shown).  We previously found 
that substrate-induced DAT trafficking was SYN1A-dependent (Furman et al. 2009, 
Johnson et al. 2005a) in GFP-DAT N2A cells, therefore we wished to test whether DAT 
and SYN1A interact endogenously in this cell system.  We found a baseline interaction of 
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DAT and SYN1A.  As shown in figure 4.3B, AMPH stimulates DAT/SYN1A 
interactions at 30 seconds of treatment; however, no change is seen after 5 minutes of 
treatment (Figure 4.3B).  Alternative statistical analysis using a one-sample t-test 
revealed a significant increase in 30 second AMPH-pretreated cells (p < 0.05 as 
compared to a hypothetical value of 1). 
DAT interacts with an ‘open’ conformation of syntaxin 
While it is known that SYN1A binds to the N-terminus of DAT, the conformation 
of SYN1A that binds to DAT is not known.  In order for SYN1A to interact with other 
SNARE proteins, it must be in an ‘open’ conformation in which the SNARE motif of 
SYN1A is accessible (Dulubova et al. 1999).  A double mutant of SYN1A (L165A, 
E166A) located in the linker region creates an ‘open’ form of SYN1A which does not 
bind to munc18 in vitro, and weakly binds munc18 in vivo (Dulubova et al. 1999, Liu et 
al. 2004). We utilized this mutant to determine whether DAT and an open form of 
SYN1A are able to interact.  The open and wild-type forms of syntaxin utilized in this 
experiment were tagged with a fluorescent tag (cyan fluorescent protein, CFP) in order to 
detect the protein and determine its approximate location in the cell.  As shown in figure 
4.4A, both the wild-type CFP syntaxin (left) and the open mutant CFP syntaxin (right) 
are expressed well in the DAT-N2A cells following transient transfection.  While there is 
a significant portion of syntaxin in the cytosol, there is also a considerable portion in the 
plasma membrane as depicted by the thin blue line encircling the cell.  The fact that we 
can detect SYN1A at the plasma membrane suggests that proper trafficking is occurring.  
Munc18 aids in the proper trafficking and localization of syntaxin (Medine et al. 2007, 
Rowe et al. 2001) therefore the open mutant of syntaxin which does not bind munc18 
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well has some impairment of trafficking.  This was noted in our immuno-precipitation 
studies where we found ~50 % less ‘open’ mutant CFP-SYN1A in the plasma membrane 
as compared to wild-type CFP-SYN1A (mean membrane total OD of ‘open’ syntaxin: 
10.76 arbitrary units v. wild-type syntaxin: 20.57 arbitrary units; p < 0.001 by paired t-
test).  We are able to differentiate the exogenously added SYN1A from the endogenous 
SYN1A due to the CFP tag on the exogenous syntaxin which adds ~26 kDa to the 
molecular weight.  Our immuno-precipitation studies of DAT and SYN1A show that both 
the wild-type and open form of CFP-SYN1A co-immuno-precipitate with DAT (Figure 
4B).  There was no significant difference (p = 0.4) between the mean OD of syn/mem 
syn/rel DAT value in the wild-type CFP-SYN 1A (0.576 ± 0.07 arbitrary units) v. ‘open’ 
mutant CFP-SYN1A (0.792 ± 0.23 arbitrary units). 
Discussion 
The aim of this study was to determine the role of SYN1A in basal DAT 
trafficking and function and determine whether the AMPH-stimulated increase in 
DAT/SYN interaction was trafficking dependent.  Here we show that SYN1A is 
necessary for proper constitutive DAT trafficking and function since cleavage of SYN1A 
in rat synaptosomes significantly reduced [3H]DA uptake, AMPH-stimulated DA efflux 
and DAT surface expression.  We find that AMPH stimulates DAT/SYN interactions at 
times commensurate with its effect to induce rapid trafficking of DAT to the plasma 
membrane.  Our data correlate with Sung et al., (2003, Sung & Blakely 2007) who found 
decreased norepinephrine transport through NET in rat cortical synaptosomes as well as 
other systems in the presence of BoNT/C.  We found that AMPH-stimulated DA efflux 
was also reduced in the presence of BoNT/C suggesting that SYN1A regulates AMPH-
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mediated effects.  A decrease in AMPH-stimulated DA efflux could simply be due to the 
decrease in DAT surface expression which would limit the availability of DAT for 
AMPH to bind. However, since SYN1A targets the N-terminus of DAT which is known 
to regulate AMPH-stimulated DA efflux, it is also possible that SYN1A modulates 
AMPH-stimulated DA efflux through binding to the N-terminus.  We found that AMPH 
increases the basal DAT/SYN1A interaction in rat synaptosomes and DAT-N2A cells to 
approximately ~2-fold after 30 seconds of treatment.  The increase in DAT/SYN1A 
interaction following AMPH treatment correlated in time with the AMPH stimulated 
DAT trafficking to the plasma membrane observed in rat synaptosomes and DAT N2A 
cells (Furman et al. 2009, Johnson et al. 2005a).  Therefore, it is possible that AMPH 
stimulates the increase in the DAT/SYN1A interaction by inducing DAT trafficking to 
the plasma membrane where DAT and SYN1A interact.  In DAT-N2A cells, 5 minute 
treatment of 10 µM AMPH had no effect on DAT/SYN1A interactions.  In contrast, 
Binda et al., (2008) found that 10 µM AMPH for 5 minutes could increase DAT/SYN1A 
interactions in mouse synaptosomes and DAT-HEK cells overexpressing SYN1A. These 
discrepancies may be due to variations in systems since N2A cells endogenously express 
SYN1A whereas HEK cells do not.  In addition, N2A cells and HEK cells may have 
differences in DAT trafficking properties which may also contribute to differences in 
SYN1A regulation.  In this study, AMPH-stimulated DAT/SYN1A interactions were not 
measured at 5 minutes in rat synaptosomes therefore we can’t make any conclusions for 
this time point. 
It is also of interest to know the biochemical characteristics of the DAT/SYN1A 
interaction.  At this stage, it is known that SYN1A binds to the N-terminus of DAT but 
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the form of SYN1A is not known.  Furthermore, it is not known whether other SNARE 
proteins such as SNAP25 or regulators of SYN1A such as munc18 may also co-immuno-
precipitate with DAT.  Use of an open mutant form of SYN1A has aided in the 
understanding of conformational changes of SYN1A upon binding to SNARE proteins 
and other regulatory proteins (Dulubova et al. 1999).  We used the ‘open’ SYN1A mutant 
in order to determine whether DAT can bind to an open form of SYN1A. Immuno-
precipitation studies demonstrate that the ‘open’ mutant of SYN1A co-immuno-
precipitates with DAT to the same degree as wild-type SYN1A.  These results are 
somewhat perplexing if we assume that wild-type SYN1A adopts an open conformation 
50% of the time and a closed conformation 50% of the time.  However, if wild-type 
SYN1A adopts an open conformation the majority of the time, for example 80% or more, 
then wild-type and open mutant SYN1A may bind to DAT to a similar degree.  It is 
possible that overexpression of wild-type SYN1A may result in more open forms of 
SYN1A since proteins that keep it in a closed conformation such as munc18 are not 
overexpressed.  More experiments such as in vitro binding assays are needed to 
determine the degree of open SYN1A binding to DAT.  
    Overall, we find that SYN1A is a necessary component of basal and stimulated 
DAT trafficking and function and future studies should address the role of DAT 
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Dopaminergic neurotransmission regulates normal physiological functions as well 
as disease states including psychosis, Parkinson’s Disease, ADHD and drug addiction.  In 
order to develop and improve treatments for these disease states, it is necessary to 
understand the basic neuropharmacological properties of dopaminergic 
neurotransmission in general and potential drug targets such as DAT in particular.  The 
purpose of this thesis was to further characterize the regulation of DAT activity by 
constitutive and stimulated DAT trafficking.  Previous research in the field of DAT 
trafficking has provided some insight into the regulation of DAT trafficking. 
Based on previous research discussed in Chapter I, the following DAT trafficking 
model could be proposed whereby (1) DAT constitutively recycles from the plasma 
membrane into early and recycling endosomes; (2) In response to various stimuli 
including prolonged substrate treatment, and prolonged PKC activation, DAT 
endocytosis is predominant and a reduction in DAT surface expression occurs; (3) recent 
studies demonstrate that rapid treatment with various stimuli increases DAT trafficking 
towards the membrane leading to increased surface expression.  
 Based on research presented in this thesis (Chapters II, III and IV), an extended 
DAT trafficking model is proposed whereby (1) constitutive DAT recycling from the 
plasma membrane into early and recycling endosomes is regulated by Rab 11 and 
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syntaxin 1A (Chapters III and IV); (2) Rapid DAT trafficking to the plasma membrane 
occurs in response to both AMPH as well as the physiological substrate DA in a PKC-β 
dependent, D2 receptor independent manner (Chapter II); (3) As in the previous model, 
DAT endocytosis occurs in response to prolonged substrate treatment.  
Constitutive DAT trafficking 
Studies in DAT-PC12 and CFP-DAT PAE cells demonstrated that DAT 
constitutively recycles into early and recycling endosomes in a clathrin-dependent 
manner at an approximate rate of 3-5 %/min (Loder & Melikian 2003, Melikian & 
Buckley 1999, Sorkina et al. 2003, Sorkina et al. 2005).  Recent studies in live ventral 
midbrain dopaminergic neurons demonstrate constitutive recycling in a physiological 
system (Eriksen et al. 2009). 
Rab 11 was used as a marker of the recycling endosome in studies with PAE cells 
and DAT co-localized with Rab 11 under basal conditions (Sorkina et al. 2003).  In DAT-
N2A cells, we found that a constitutively active mutant of Rab 11 increases basal surface 
expression of DAT with a concomitant increase in [3H]DA uptake (Chapter III).  
Furthermore, a dominant negative mutant of Rab 11 decreased DAT surface expression.  
These data suggest a role for Rab 11 in facilitating DAT trafficking to the plasma 
membrane.  Rab 11 also regulates trafficking of the well-known recycling protein 
transferrin (Ren et al. 1998, Ullrich et al. 1996) which co-fractionates and co-localizes 
with DAT (Melikian & Buckley 1999, Sorkina et al. 2005).  Based on substantial 
evidence from the Melikian and Sorkin groups, the carboxy terminus of DAT contains 
endocytic signals and is self-sufficient to undergo endocytosis whereas the amino 
terminus is not required for endocytosis and may contain membrane retention signals 
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(Holton et al. 2005, Sorkina et al. 2005, Sorkina et al. 2009, Boudanova et al. 2008b).  
Based on these data, it is possible that Rab 11 may act through the amino terminal to 
increase membrane retention or through the carboxy terminal to inhibit endocytosis.  
Alternatively, Rab 11 may act as a tether of DAT-containing vesicles to the plasma 
membrane and increase the likelihood of DAT fusion.  Future studies with Rab 11 and 
DAT should address whether there is a direct or indirect interaction between these two 
proteins and whether Rab 11 increases DAT surface expression by increasing exocytosis 
or decreasing endocytosis.   
 SYN1A is a SNARE protein that regulates transport activity of several 
transporters including NET, GAT and DAT (Quick 2006).  The mechanism of SYN1A 
regulation of neurotransmitter transporters is complex since SYN1A affects intrinsic 
activity and fusion of transporters such as NET (Sung et al. 2003, Sung & Blakely 2007).  
We found that under basal conditions, SYN1A cleavage decreases DAT surface 
expression, [3H]DA uptake and AMPH-stimulated DA efflux in rat synaptosomes.  Based 
on these data, SYN1A is required for basal DAT trafficking to the plasma membrane or 
retention at the plasma membrane.  DAT and SYN1A primarily interact at the plasma 
membrane (Binda et al. 2008), so retaining DAT on the plasma membrane is a plausible 
mechanism for SYN1A regulation of DAT.  However, since SYN1A is a critical SNARE 
protein it is equally as likely that DAT can’t fuse to the plasma membrane in the absence 
of SYN1A.  Data from chapter II (discussed below) suggest that SYN1A is required for 
DAT fusion to the plasma membrane.  Future studies should address whether SYN1A 
modulates DAT activity through fusion regulation, a direct interaction, or both.   
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 Thus far, it is clear that DAT endocytoses into early and recycling endosomes; 
however it is not known whether there are intermediate compartments to which DAT 
recycles prior to plasma membrane fusion.  A ‘readily releasable pool’ (RRP) has been 
hypothesized for trafficking proteins in neurosecretory cells (Schmidt et al. 1997). The 
‘readily releasable pool’ would likely be close to the plasma membrane.  Based on 
images of DAT in TIRFM (discussed in Chapter II), it appears that there are many DAT 
molecules that are not at the plasma membrane but lie directly underneath the membrane. 
The RRP must also contain important proteins necessary for DAT fusion to the plasma 
membrane such as the SNARE protein VAMP2 (discussed in the next section) as well as 
Rab 11 assuming its function is to tether DAT-containing vesicles to the plasma 
membrane. 
 My proposed model for constitutive DAT trafficking (Figure 5.1) based on 
current literature as well as data presented in chapters III and IV is the following: DAT 
undergoes constitutive recycling to the plasma membrane via the endocytic recycling 
compartment/recycling endosome (ERC) and a yet unidentified readily releasable pool 
(RRP).  Rab 11 mediates tethering of the RRP to the plasma membrane thus increasing 
the likelihood of DAT fusion.  Once DAT is in the RRP, SYN1A facilitates DAT fusion 
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AMPH, stimulates DAT endocytosis following prolonged treatment (Chi & Reith 2003, 
Gulley et al. 2002, Little et al. 2002, Saunders et al. 2000).  
 The SNARE protein SYN1A regulates basal DAT trafficking (described above) 
as well as stimulated DAT trafficking.  We found that cleavage of either SYN1A or 
VAMP2 blocked substrate-stimulated DAT trafficking to the plasma membrane (Chapter 
II).  Additionally, in Chapter IV, we found that AMPH stimulates the DAT/SYN1A 
interaction (previously described: (Binda et al. 2008, Lee et al. 2004) in DAT-N2A cells 
and rat synaptosomes at times commensurate with AMPH-stimulated DAT trafficking to 
the plasma membrane.  Taken together these data suggest a synergistic effect whereby 
AMPH-stimulated trafficking of DAT requires SYN1A and SYN1A interaction with 
DAT is stimulated by AMPH.  It remains to be determined whether SYN1A regulates 
DAT trafficking simply by regulating DAT fusion or whether the DAT/SYN1A 
interaction is necessary for AMPH-stimulated DAT trafficking to the plasma membrane.  
It is possible that AMPH could stimulate DAT/SYN1A interaction simply by increasing 
the number of DAT molecules that are at the plasma membrane thereby increasing the 
likelihood of DAT and SYN1A interaction.  Alternatively, SYN1A could interact with 
DAT immediately prior to DAT fusion which would make the DAT/SYN1A interaction 
essential for AMPH-stimulated DAT trafficking.  Elegant future studies should address 
these questions and determine whether AMPH-stimulated DAT trafficking can occur 
when SYN and DAT are unable to directly interact.   
 Figure 5.2 depicts a proposed model for rapid-substrate stimulated DAT 
trafficking based on data from chapters II, III and IV.  This model assumes that proteins 
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(WT) litter mates (Chen et al. 2009).  Interestingly, AMPH-stimulated DAT trafficking 
showed opposite trends in PKC-β knock-out mice compared to WT.  Rapid treatment of 
AMPH decreased DAT surface expression and prolonged AMPH treatment increased 
DAT surface expression in KO mice.  These data support findings from Furman et al., 
2009 and overall suggest a role of PKC-β in AMPH regulation of transporter trafficking.  
Based on these data, it may be hypothesized that AMPH and PKC regulate DAT 
trafficking through a common mechanism or pathway. This hypothesis is challenged by 
recent data that suggests that AMPH and PKC-mediated internalization operate through 
different pathways (Boudanova et al. 2008a). However, these data specifically look at 
prolonged AMPH and PKC-induced internalization and it is extremely possible that 
signaling pathways that regulate DAT trafficking to the plasma membrane are completely 
independent of pathways that regulate DAT endocytosis.  Thus, PKC and AMPH may 
operate within the same pathway during DAT exocytosis but different pathways during 
DAT endocytosis.  The D2 receptor agonist quinpirole increases DAT surface expression 
within one minute of treatment in DAT-N2A cells that overexpress D2 receptor (Bolan et 
al. 2007).  Additionally, Lee et al., (2007) found a direct interaction between the D2 
receptor and DAT.  We found that rapid DA-stimulated DAT trafficking is not dependent 
on activation of D2 receptors, at least in DAT-N2A cells (Chapter II).  However, it is 
highly likely that DA or AMPH treatment has some effect on D2 in systems that contain 
both DAT and D2R since DA can directly activate D2Rs and AMPH-stimulated DA 
efflux will lead to D2 receptor activation.  Thus, it is entirely possible that DA stimulates 
a D2R-independent and D2R-dependent pathway. 
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Significance and Future Directions 
In summary, this thesis demonstrates a role of Rabs and SNAREs in constitutive 
DAT trafficking to the plasma membrane as well as a PKC-dependent role of substrates 
in rapid DAT trafficking to the plasma membrane.  Since much of the current and 
previous research has focused on the long-term substrate-induced DAT endocytosis, this 
research provides exciting new information about the process of DAT exocytosis. 
Exogenous administration of the natural substrate DA rapidly increases DAT 
surface expression within one to two minutes of application.  This finding suggests a 
homeostatic mechanism to regulate extracellular DA levels.  An increase in DAT surface 
expression following exogenous application of dopamine would allow for increased 
reuptake of extracellular DA back into the nerve terminal which would help to restore the 
physiological levels of dopaminergic neurotransmission.  The substrate AMPH may 
trigger the same homeostatic response since AMPH is structurally homologous to DA. 
Alternatively, in a physiological system, AMPH-stimulated DA efflux would lead to 
increased extracellular DA and DA may directly trigger the increase in DAT surface 
expression.  The sensor for this DAT up-regulation is likely the transport of substrates 
through DAT since transport is required for the increase in surface expression.   The 
mechanism of PKC-β regulation of substrate-stimulated DAT trafficking is an area of 
current investigation in the Gnegy lab.  It is possible that PKC-beta affects DAT 
trafficking through indirect phosphorylation of a PKC substrate such as RACK1 (receptor 
of activated protein kinase C) which binds to the N-terminus of DAT. 
The finding that Rab 11 function regulates DAT surface expression and function 
under basal conditions suggests that DAT trafficking to the plasma membrane is tightly 
regulated.  Based on these data, we may start to consider DAT and other monoamine 
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transporters to undergo classic recycling similar to receptors such as the transferrin 
receptor.  Further studies should address whether Rab proteins are involved in substrate 
stimulated DAT trafficking to the plasma membrane.  Increased Rab 11 function leads to 
increased DAT surface expression and subsequently more re-uptake of DA indicating a 
negative regulation of Rab 11 on dopaminergic neurotransmission.   
Our studies with SNARE proteins syntaxin 1A and VAMP-2 demonstrate a 
necessary role for these proteins in DAT trafficking and function.  These findings extend 
the role of SNARE proteins from regulators of classic secretory vesicle fusion to 
regulators of transporter fusion to the plasma membrane.  An important question for 
future research studies is identifying the source of DAT that trafficks to the plasma 
membrane constitutively and in response to substrates.  It is likely that the source of DAT 
is small synaptic-like vesicles which contain Rab 11 and VAMP-2 to regulate tethering 
and fusion respectively.   
Taken together DAT trafficking and function are rapidly and specifically 
regulated by intracellular stimuli including protein kinase activation and GTPase protein 
regulation as well as extracellular stimuli including the physiological substrate DA and 
the psychostimulant amphetamine. These data confirm the importance of DAT in 
maintaining proper dopaminergic neurotransmission and demonstrate that homeostatic 
mechanisms are in place to rapidly modulate DAT function in response to exogenous 
stimuli.  
Overall conclusions 
 Over the last 10 years, there has been a boom of research on DAT trafficking.  
Much knowledge has been gained regarding constitutive and regulated DAT trafficking 
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in a variety of heterologous cell and primary culture systems.  With the advent of 
advanced imaging techniques along with standard research tools, we are able to visualize 
and monitor living cells in action.  The overall goal of research on constitutive DAT 
trafficking is to understand precisely how physiological dopaminergic neurotransmission 
works so that in circumstances in which there is injury, deficits or abnormal regulation, a 
treatment may be developed.  Similarly, with regulated DAT trafficking, given that many 
current licit and illicit drugs target DAT as well as other monoamine transporters, it is 
absolutely essential that we understand the mechanism of these drugs so that new 
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